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Abstract
The American College of Cardiology Foundation in
collaboration with the Heart Rhythm Society and key
specialty and subspecialty societies conducted a review of
common clinical scenarios where implantable cardioverter-
defibrillators (ICDs) and cardiac resynchronization ther-
apy (CRT) are frequently considered. The clinical sce-
narios covered in this document address secondary
prevention, primary prevention, comorbidities, generator
replacement at elective replacement indicator, dual-chamber
ICD, and CRT.
The indications (clinical scenarios) were derived from
common applications or anticipated uses, as well as from
current clinical practice guidelines and results of studies
examining device implantation. The 369 indications in this
document were developed by a multidisciplinary writing
group and scored by a separate independent technical panel
on a scale of 1 to 9 to designate care that is Appropriate
(median 7 to 9), May Be Appropriate (median 4 to 6), and
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March 26, 2013:1318–68 Appropriate Use Criteria for ICD/CRTRarely Appropriate (median 1 to 3). The final ratings reflect
the median score of the 17 technical panel members: 45% of
the indications were rated as Appropriate, 33% were rated May
Be Appropriate and 22% were rated Rarely Appropriate.
In general, Appropriate designations were assigned to
scenarios for which clinical trial evidence and/or clinical
experience was available that supported device implantation.
By contrast, scenarios for which clinical trial evidence was
limited or device implantation seemed reasonable for exten-
uating reasons were categorized as May Be Appropriate.
Scenarios for which there were data showing harm, or no
data were available, and medical judgment deemed device
therapy ill-advised were categorized as Rarely Appropriate.
For example, comorbidities including life expectancy and
cognitive function impacted appropriateness ratings.
The Appropriate Use Criteria for ICD/CRT have the
potential to enhance physician decision making, healthcare
delivery, and reimbursement policy. Furthermore, recogni-
tion of clinical scenarios rated as May Be Appropriate
facilitates the identification of areas that would benefit from
future research.
Preface
In an effort to respond to the need for the rational use of
cardiovascular services including imaging and invasive pro-
cedures in the delivery of high-quality care, the American
College of Cardiology Foundation (ACCF) in collaboration
with the Heart Rhythm Society (HRS) has undertaken a
process to describe the appropriate use of implantable
cardioverter-defibrillators (ICDs) and cardiac resynchroni-
zation therapy (CRT) for selected patient populations.
Appropriate use criteria (AUC) publications reflect an
ongoing effort by the ACCF to critically and systematically
create, review, and categorize clinical situations where phy-
sicians utilize diagnostic tests and procedures to care for
patients with cardiovascular disease. The process is based on
current understanding of the benefits and risks of the
procedures examined. Although impossible to be entirely
comprehensive given the wide diversity of clinical disease,
the indications are meant to identify common clinical
scenarios encompassing the majority of situations encoun-
tered in contemporary practice. Given the breadth of
information they convey, the indications do not directly
correspond to the Ninth Revision of the International Clas-
sification of Diseases system, as these codes do not include
clinical information such as disease severity or symptom
status.
The ACCF and HRS believe that careful blending of a
broad range of clinical experiences and available evidence-
based information will help guide a more efficient and
equitable allocation of healthcare resources in cardiovascular
care and device implantation. The ultimate objective of
AUC is to improve patient care and health outcomes in a
cost-effective manner, but it is not intended to ignoreuncertainty and nuance intrinsic to clinical decision making.
Therefore, AUC should not be considered substitutes for
sound clinical judgment and practice experience.
The AUC process itself is also evolving. The initial AUC
documents were directed primarily towards noninvasive
cardiovascular imaging tests. Revisions to several of these
imaging documents have already been published (1–3). The
goal for the AUC process is to provide contemporary
reference documents that incorporate new research in a
timely manner, including the results of AUC implementa-
tion studies. AUC for ICD and CRT is the third in a more
recent series of AUC documents that examine the use of
invasive procedures (4,5). Because ICDs and CRT play a
central role in the care of patients with cardiovascular
disease, guidance around the rationale and evidence-based
use of the procedure is the goal of the current document.
Andrea M. Russo, MD, FACC, FHRS
Co-Chair, ICD/CRT Writing Group
Raymond F. Stainback, MD, FACC, FASE
Co-Chair, ICD/CRT Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
1. Introduction
The American College of Cardiology Foundation (ACCF),
in collaboration with the Heart Rhythm Society (HRS),
developed common clinical scenarios where implantable
cardioverter-defibrillators (ICDs) and cardiac resynchroni-
zation therapy (CRT), also known as biventricular pacing,
are frequently considered. These implanted devices are also
collectively referred to as cardiovascular implantable elec-
tronic devices (CIEDs). The indications, as presented in
these clinical scenarios, were derived from common presen-
tations or anticipated uses, as well as from current clinical
practice guidelines. The 369 indications in this document
were developed by a writing group with diverse clinical
expertise and rated by a separate independent technical
panel on a scale of 1 to 9, to designate care that is
Appropriate (median 7 to 9), May Be Appropriate (median
4 to 6), and Rarely Appropriate (median 1 to 3). Members
of the writing group and the technical and review panels
were selected in large part because of their active involve-
ment in the clinical practice of electrophysiology, heart
failure, and other related areas of cardiovascular medicine.
Describing the appropriate use criteria (AUC) for ICD
and CRT has the potential to enhance physician decision
making, healthcare delivery, and reimbursement policy.
Furthermore, recognition of clinical scenarios categorized as
May Be Appropriate facilitates identification of areas that
would benefit from future research.
This report addresses the appropriate use of ICD and
CRT. Determination of the criteria for the implantation of
ICDs and/or CRT is based on the results of evidence
1322 Russo et al. JACC Vol. 61, No. 12, 2013
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incorporated into clinical practice guidelines. However,
there is also recognition that in “real world” scenarios, expert
opinion is of value in addressing patient populations that are
either not represented in currently available randomized
clinical trials or for treatment recommendations that are
supported by lower levels of evidence. In addition, it is
important to recognize that when patients are excluded
from a clinical trial, the results of the trial should not be
interpreted to mean that the treatment was proven to be
ineffective for patients who were excluded. Physicians must
use their best judgment in deciding whether a treatment
might be beneficial to patients who would have been
excluded from a clinical trial. Accordingly, the AUC were
designed to include a broad spectrum of clinical scenarios
representative of those encountered by physicians in their
daily practice. The AUC are also intended to highlight areas
of potential misapplication of technology (overutilization) in
addition to areas of possible underutilization. For practical
implementation, the document was not designed to be all
encompassing, and therefore, the writing group focused on
the more commonly encountered scenarios. As with other
AUC documents, there is an implicit acknowledgment that
important deficiencies may be revealed by subsequent clin-
ical trials and AUC implementation studies, which will not
only guide further research but also inform expedient
updates in the AUC for ICD/CRT. As the field advances,
the healthcare community needs to understand how to best
incorporate this technology into daily clinical care. The
ACCF and the HRS are dedicated to this effort.
2. Methods
A detailed description of the methods that were used for
rating the selected clinical indications can be found in a
previous publication, “ACCF Proposed Method for Evalu-
ating the Appropriateness of Cardiovascular Imaging” (6).
Briefly, this process combines evidence-based medicine and
practice experience by engaging a technical panel in a
prospective, modified Delphi exercise. The technical panel
was created through nominations given by multiple relevant
professional societies and provider-led organizations as well
as from health policy and payer communities. To preserve
objectivity, technical panels are created so as to not include
a majority of individuals whose livelihood is tied to the
technology under evaluation. During the development of
this document, the AUC Task Force finalized a revision of
the terminology and definitions to better clarify the appro-
priateness categories (7). As a result, the technical panel
used the terminology described in the original methodology
paper for all but the last round of rating. Further explana-
tion of this change is provided in the following text.
In making its appropriateness determinations, the tech-
nical panel was provided with relevant evidence from the
medical literature and practice guidelines. Technical panel-ists were asked to individually assess the benefits and risks of
device implantation. Then, following a group discussion of
the indications and related considerations, a second individ-
ual rating process was performed to determine the final
ratings. After the rating process, the final appropriate use
ratings were summarized using an established rigorous
methodology (8).
Indication Development
The indications were constructed by a writing group with
expertise in both the science and clinical practice of elec-
trophysiology, heart failure, general cardiology, invasive
cardiology, and noninvasive cardiac imaging. The writing
group was tasked with developing a list of clinical scenarios
covering the majority of patients that clinicians might
consider referring for device implantation. The term “indi-
cation” is used interchangeably with “clinical scenario” in
the document for brevity and does not imply that a
procedure should necessarily be performed. Indication mod-
ifications were made through discussions with the ACCF
AUC Task Force and feedback from reviewers that included
additional experts in the areas noted in the preceding text,
along with experts in the fields of geriatric medicine,
internal medicine, and clinical outcomes research.
The indications included in this publication incorporate a
wide range of cardiovascular signs, symptoms, disease states,
and physiological assessments, including, but not limited to,
measurement of the left ventricular ejection fraction
(LVEF), duration of the QRS complex, monitoring data,
and results of electrophysiological studies. Within each
main disease category, a standardized approach was used to
capture the majority of clinical scenarios with an attempt to
avoid making the list of indications excessive. This docu-
ment does not cover indications for implantation of devices
in the pediatric population.
Wherever possible, indications were mapped to relevant
clinical guidelines and key publications/references (see
Guideline Mapping and References Online Appendix).
Rating Process and Scoring
The technical panel first rated the indications indepen-
dently. Then, the technical panel convened for a face-to-
face meeting to discuss each indication. At this meeting,
panelists were provided with their scores and a blinded
summary of their peers’ scores. After the meeting, panelists
once again independently rated each indication to indicate
their final scores. The technical panel completed an addi-
tional rating process to address a few areas that required
further clarification and readdressed ratings following the
introduction of revised terminology as outlined in the
recently updated methods document (7).
The members of the technical panel completed the rating
process using the old terminology and definitions (appro-
priate, uncertain, and inappropriate, as described in the
original methods [6]), and were subsequently asked to
participate in an additional round of rating to re-examine
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definitions. The new terminology was finalized after the
technical panel had completed the rating process. As a
consequence, the additional round of rating was deemed
necessary to minimize potential confusion related to differ-
ences in terminology between the old and updated meth-
odology and to assess whether the change could impact the
appropriateness classification of the different clinical scenar-
ios. The final rating of the indications using the revised
terminology and expanded definitions resulted in a change
in ratings for only 1% of the total indications.
When rating each clinical scenario, the technical panel
was asked to assess whether device implantation is Appro-
priate, May Be Appropriate, or Rarely Appropriate, accord-
ing to the following definition of appropriate use:
ICD and/or CRT implantation is appropriate in general
when the expected value in terms of survival and/or other
health benefits (symptoms, functional status, and/or
quality of life) exceed the potential adverse health con-
sequences relating to the acute procedural risk and the
long-term consequences of living with an implanted
device.
The technical panel scored each indication as follows:
Median Score 7 to 9: Appropriate care
An appropriate option for management of patients in
this population due to benefits generally outweighing
risks; effective option for individual care plans, although not
always necessary, depending on physician judgment and
patient-specific preferences (i.e., procedure is generally ac-
ceptable and is generally reasonable for the indication).
Median Score 4 to 6: May Be Appropriate care
At times an appropriate option for management of
patients in this population due to variable evidence or
agreement regarding the benefit/risk ratio, potential benefit
based on practice experience in the absence of evidence,
and/or variability in the population; effectiveness for indi-
vidual care must be determined by a patient’s physician in
consultation with the patient based on additional clinical
variables and judgment along with patient preferences (i.e.,
procedure may be acceptable and may be reasonable for the
indication).
Median Score 1 to 3: Rarely Appropriate care
Rarely an appropriate option for management of pa-
tients in this population due to the lack of a clear benefit/
risk advantage; rarely an effective option for individual care
plans; exceptions should have documentation of the clinical
reasons for proceeding with this care option (i.e., procedure
is not generally acceptable and is not generally reasonable
for the indication).
The division of these scores into 3 levels of appropriate-
ness should be viewed as a continuum. When there is
diversity in opinion regarding the management of a partic-ular clinical scenario such that scores fall in the intermediate
level of appropriateness, they are labeled May Be Appro-
priate, as critical patient information or research data may
be lacking or discordant. This must not be treated as either
Appropriate or Rarely Appropriate, but rather as a distinct
category of May Be Appropriate. It is anticipated that the
AUC standards will continue to be revised as further data
are generated and information from the implementation of
the criteria is accumulated.
The level of agreement among panelists as defined by
RAND (8) is analyzed based on the BIOMED rule. For
each clinical scenario, the voting process produces a result in
which there is either mathematical agreement or disagree-
ment among panelists. Agreement exists when 4 or fewer
panelists’ ratings fell outside the 3-point region containing
the median score.
Disagreement exists when 5 or more panelists’ ratings fall
in both the Appropriate and the Rarely Appropriate cate-
gories. Any indication having disagreement will be placed in
the May Be Appropriate category regardless of the final
median score. The final scores were obtained after the panel
had the opportunity to discuss the clinical scenarios at a
face-to-face meeting that was followed by a second-round
rating to eliminate the possibility of misinterpretation of
either the indication wording or the published clinical data.
3. Assumptions
To limit inconsistencies in interpretation, specific assump-
tions were considered by the writing group in development
and were used by the technical panel in rating the clinical
indications for the appropriate use of device implantation.
Other assumptions also reviewed in the Discussion relate to
the interpretation of AUC results and implementation.
General Clinical Assumptions
1. For each indication, the rating should reflect whether
device implantation is reasonable for the patient accord-
ing to the appropriate use definition. It should not be
assumed that for each indication the decision to treat
has already been made.
2. A qualified clinician has completed a thorough clinical
history and physical examination such that the clinical
status of the patient can be assumed to be valid as stated
in the indication. For example, a patient said to be
asymptomatic is truly asymptomatic for the condition
in question, and sufficient questioning of the patient has
been undertaken.
3. End-of-life discussion, advanced directive, and patient
consent have been adequately addressed. Patients are
assumed to be candidates for ICD/CRT only after a
decision-making discussion has been undertaken be-
tween the patient, appropriate family and/or legal
decision makers, and the physician. It is assumed that
the patient and/or decision makers are educated suffi-
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plantation is consistent with current care intentions or
with prior advance directives.
4. The clinical scenarios should be preferentially rated
based on evidence from published literature and clinical
practice guidelines regarding the risks and benefits of
ICD/CRT. Selected specific patient groups not well
represented in the literature or in clinical practice
guidelines are presented in many of the current clinical
scenarios because the writing group recognizes that
decisions about device implantation in such patients are
frequently required. Examples of such patients include
those with end-stage renal disease or advanced age.
5. All patients are receiving optimal care, also called
“guideline-directed medical therapy” (GDMT) in
ACC/AHA Clinical Practice Guidelines, including
guideline-based risk factor modification for primary or
secondary prevention for coronary artery disease (CAD)
and heart failure in cardiovascular patients unless spe-
cifically noted (9).
6. There are no unusual extenuating logistical or process-
of-care circumstances such as inability to comply with
follow-up due to any number of reasons (e.g., mental
instability, lack of transportation) unless specifically
noted.
7. There are no technical limitations for device implanta-
tion or other comorbidities that are likely to substan-
tially increase procedural risk, unless specifically noted.
8. Coronary artery disease: for sections that reference
revascularization, additional assumptions may apply,
including but not limited to the following:
a. For scenarios in which no revascularization is
planned, it should be assumed that revascularization
is not indicated unless otherwise specified, for ex-
ample, there are no major epicardial coronary lesions
measuring 70% (non-left main) or 50% (left
main) or no evidence of ischemia by fractional flow
reserve or perfusion imaging.
b. Other scenarios may include cases where patients are
not candidates for revascularization for whatever
reason, including but not limited to severe, diffuse
CAD that is not amenable to revascularization.
c. When revascularization is considered or performed,
it is assumed that patients are also acceptable can-
didates for revascularization based on the absence of
other noncardiac comorbidities that would be a
contraindication for revascularization.
d. If patients are candidates for revascularization, and
revascularization is planned, electrophysiology (EP)
testing should not be performed until after the
intended revascularization is performed.
e. An ICD should not be implanted before revascular-
ization to circumvent the current Centers for Medi-
care & Medicaid Services 3-month waiting-period
rule (10,11).9. An assessment of the LVEF during hospitalization
following acute infarction or revascularization generally
prompts consideration of ICD/CRT implantation.
When a subsequent waiting period is required (e.g.,
after guideline-directed medical therapy, myocardial
infarction, or revascularization), it is assumed that the
final decision to treat will be based on a follow-up
LVEF assessment after expiration of the waiting pe-
riod, and that the imaging facility understands that
quantitative measurement of the LVEF is an important
goal of the exam.
Practice Parameters/Standard of Care
10. Operators performing device implantation have appro-
priate clinical training (12) and experience consistent
with established standards of care and have satisfactory
outcomes as assessed by quality assurance monitoring,
including national benchmark data from the National
Cardiovascular Data Registry (NCDR) ICD registry
(13). ICDs are implanted with transvenous electrodes.
Although different means of delivering electrical ther-
apy have only recently become available, specifically, a
totally subcutaneous ICD system, a standard trans-
venous approach was assumed for the purpose of this
document.
11. Geographic/regional variability: issues of local availabil-
ity of skill in performing the procedure should not be
considered during the rating process, as it is assumed
that skilled operators and appropriate implantation
resources are locally available.
12. Adjunctive cardiac imaging modalities are often re-
quired for appropriate patient selection. These may
include coronary angiography or cardiac computed
tomography for the determination of coronary anatomy
in addition to other noninvasive cardiac imaging mo-
dalities, including echocardiography, cardiac magnetic
resonance imaging, and radionuclide imaging for initial
assessment of cardiac structure and function (LVEF)
and when needed, a follow-up determination of the
LVEF. It assumed that laboratories performing these
services have appropriate clinical training and experi-
ence, perform these studies and interpret them accord-
ing to national standards, and have satisfactory out-
comes as assessed by quality improvement monitoring.
13. It is recognized that there may be variability in the
measurement of the LVEF at different points in time
and utilizing different imaging modalities. The labs
performing the LVEF assessments will have quality
assurance measures in place to ensure accuracy of each
individual method for determining and reporting left
ventricular (LV) function.
14. For all indications, it is assumed that the LVEF stated
in the indications was measured within a timeframe
relevant to making the decision about eligibility for
ICD implantation. It is assumed that repeat evaluation
of the LVEF will be performed after an appropriate
11
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infarction or revascularization, or following GDMT in
the setting of a new diagnosis of heart failure or
cardiomyopathy, before determining ICD eligibility.
5. All procedures presented are to be considered for clinical
indications and not as part of a research protocol.
6. With respect to CRT, atrial arrhythmias (including
atrial fibrillation, atrial flutter, and atrial tachycardia)
are not included in the indication tables. There are
fewer data available for CRT in patients with persistent
atrial arrhythmias, and the writing group elected to
avoid additional scenarios for practical reasons, as the
document already includes a large number of scenarios.
However, it is assumed that the presence of intermit-
tent or persistent atrial arrhythmias would not preclude
CRT implantation, and the benefits of CRT would also
apply to patients with persistent atrial arrhythmias, as
long as CRT is maintained nearly 100% of the time.
7. The potential adverse effects of right ventricular (RV)
pacing in the setting of pre-existing LV systolic dys-
function are well described (14–16). Therefore, at-
tempts should be made to reduce unnecessary RV
pacing by appropriate programming of single- and
dual-chamber ICDs, whenever possible.
8. Single- versus dual-chamber ICD selection: It is as-
sumed that most patients undergoing ICD implanta-
tion who have standard dual-chamber pacing indica-
tions will undergo attempted insertion of an atrial lead
as described in the 2008 ACC/AHA/HRS device-
based therapy guidelines document, and a separate
consensus document pertaining to selection of dual-
versus single-chamber devices for pacemaker patients,
which was recently published (17). However, there is
currently controversy regarding single- versus dual-
chamber device selection in patients who do not meet
strict pacing indications but are undergoing ICD im-
plantation without CRT, and this is an area of ongoing
investigation. For example, it has been hypothesized
that the availability of dual-chamber discriminators
might improve discrimination of ventricular arrhyth-
mias from supraventricular arrhythmias and thus po-
tentially reduce unnecessary ICD shocks. However, a
recent meta-analysis demonstrated that the proportion
of patients receiving inappropriate therapy was not
different between single- and dual-chamber devices
using technology available at the time (18). It is
currently unknown whether recent advancements in
technology utilizing the most current ICD systems will
show any benefit of dual-chamber devices in the ab-
sence of standard pacing indications, and studies eval-
uating this controversial topic are currently ongoing.
Because there is a difference in cost and a potential
difference in longevity of single- versus dual-chamber
devices, and dual-chamber systems may potentially
improve discrimination between ventricular and su-
praventricular arrhythmias, but have a higher risk ofdislodgment due to the addition of the atrial lead, these
scenarios were felt to be important to address in this
document.
9. Decisions for ICD implantation should be based on a
reasonable expectation of survival with a good func-
tional status for at least 1 year. The clinical trial
populations used to derive published predictive survival
models may differ from the general heart failure pop-
ulation with regard to age and comorbidities. There-
fore, consideration should be given to advanced age
or other comorbidities that might reduce the likeli-
hood of benefit or increase the risk of ICD therapy
for individuals.
Cost/Value
20. From the standpoint of the practicing physician caring
for an individual patient, potential clinical benefits of
device implantation should be the highest priority, and
this is weighed against potential risks of the procedure.
As related to societal benefits, costs should also be
considered in relationship to potential benefits in order
to better understand comparative value. However, very
little has been done to assess cost effectiveness of ICD
or CRT treatment across a spectrum of conditions and
comorbidities. Although cost and value are clearly
important variables, which are also relevant to payers
and policymakers, it is recognized that healthcare pro-
viders typically do not primarily base individual patient
decisions about device implantation on these consider-
ations. Therefore, it is anticipated that technical panel
members rate the scenarios primarily based on risks/
benefits, although cost/value considerations may also be
taken into consideration if deemed Appropriate by
panel members for particular scenarios.
Guidance Specifically for AUC Users
21. Reducing care that is Rarely Appropriate remains a
valuable means to reduce costs and population risks of
ICD and/or CRT implantation.
22. The category of May Be Appropriate should be used
when insufficient clinical data are available for a defin-
itive categorization, or there are substantial differences
in opinion regarding the appropriateness of that indi-
cation. The absence of definitive data supporting
implantation in a particular subset of patients does
not imply lack of benefit, and in such cases, careful
investigation of the particulars of the clinical sce-
nario is warranted. The designation of May Be
Appropriate should not be used as the sole grounds
for denial of reimbursement in an individual patient.
4. Definitions
Definitions of terms used throughout the indication set are
listed here.
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The duration of heart failure symptoms is defined as the
duration of symptoms since the initial diagnosis of heart
failure to the date of the device implantation. Clinical trials
and the NCDR ICD registry have utilized time frames of
3 months, 3 to 9 months, and 9 months. The writing
group recognizes that 3 months may equate to more or less
than 90 days, depending on the calendar months. The
3-month term was chosen because it was used in some
randomized clinical trials related to timing for device
implantation and is the basis of coverage in the 2005
National Coverage Determination of the Centers for Medi-
care & Medicaid Services for nonischemic dilated
cardiomyopathy.
Dyssynchrony:
Dyssynchrony refers to “ventricular electromechanical de-
lay,” which may be identified by multiple imaging tech-
niques, including echocardiography. Prolongation of the
QRS complex is seen in approximately one-third of patients
with advanced heart failure, and this prolongation may be
associated with varying degrees of ventricular electrome-
chanical delay or “dyssynchrony.” Modifications in this
delay are often seen with CRT pacing or “resynchronization
therapy.” Studies utilizing CRT have also been performed
in patients with narrow QRS complexes in the presence of
dyssynchrony. However, no proven benefit has been dem-
onstrated in this cohort with a QRS duration120 ms (19).
Additionally, recent meta-analyses question the utility of
CRT in patients with QRS durations of 120 to 149 ms
(20,21). Enrollment criteria for CRT trials have typically
been based on a QRS duration 120 ms, regardless of
imaging techniques to evaluate the presence or absence of
dyssynchrony. There is current controversy on the role of
dyssynchrony in assessing the likelihood of response to
CRT, and this argues that dyssynchrony assessments should
not be included in consideration for CRT implantation.
Therefore, due to the enrollment criteria used in clinical
trials and the absence of consensus at this time regarding its
assessment, measurement of dyssynchrony prior to implan-
tation is not included in the AUC scenarios listed in this
ocument.
uideline-Directed Medical Therapy for
table Ischemic Heart Disease:
hen tolerated, GDMT (sometimes referred to as “optimal
edical therapy”) should include aspirin (or a thienoypyri-
ine if aspirin is not tolerated), statin therapy, angiotensin-
onverting enzyme inhibition (or an angiotensin receptor
locker) and the use of beta-blockers after myocardial
nfarction. Therapy for angina/ischemia should include at
east 1 of the following medications: beta-blockers, calcium
hannel antagonists, or nitrates. Therapy should also be
irected at optimizing the treatment of associated condi-
ions such as diabetes and uncontrolled hypertension. (uideline-Directed Medical Therapy
or Heart Failure:
DMT for heart failure in the setting of LV systolic
ysfunction requires individualization but typically should
nclude the combination of an angiotensin-converting en-
yme inhibitor or angiotensin receptor blocker and beta-
locker therapy adjusted to target doses as tolerated, with
iuretics adjusted if/as needed to control fluid retention. In
elected patients, the addition of aldosterone antagonists
nd hydralazine plus nitrate combinations should be con-
idered. Patients who are going to receive substantial benefit
rom medical treatment alone usually show some clinical
mprovement during the first 3 to 6 months. Medical
herapy is also assumed to include adequate rate control for
achyarrhythmias, including atrial fibrillation. Therefore, it
s recommended that GDMT be provided for at least 3
onths before planned reassessment of LV function to
onsider device implantation. If LV function improves to
he point where primary prevention indications no longer
pply, then device implantation is not indicated.
eart Failure:
eart failure is defined as a clinical syndrome characterized
y specific symptoms described in the medical history and
igns on the physical examination. The clinical symptoms of
eart failure may include dyspnea on exertion, orthopnea,
atigue, or fluid retention. The clinical signs may include
ugular venous pressure elevation, râles, an S3 gallop, or lower
xtremity edema. A low LVEF or diagnosis of cardiomyopathy
lone, or peripheral edema without other clinical signs of heart
ailure, does not qualify as heart failure (22).
emodynamic Instability:
atients may experience periods of clinical instability with
ypotension, heart failure symptoms, pre-syncope or syn-
ope, angina, or dyspnea. These symptoms are presumed to
esult from hypo-perfusion, with a cardiac output and/or
hythm that is inadequate to support normal organ function.
nducibility at Electrophysiological (EP) Testing:
nducibility is defined as the induction of sustained ventric-
lar tachycardia (VT) or ventricular fibrillation (VF) at EP
esting with an arrhythmia duration 30 s and/or resulting
n hemodynamic compromise using standardized stimula-
ion protocols.
yocardial Infarction (MI):
he “Universal Definition of Myocardial Infarction” was
eveloped by Thygesen and colleagues in 2007 and updated
n 2012. The multifaceted clinical criteria include timing,
echanism (infarct type), biomarker status, and size. An
levated troponin is not necessarily indicative of an acute MI
23–25).
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Low-Level Troponin Elevation:
Not infrequently, a low-level troponin elevation is detected
when blood is drawn routinely or as a consequence of
protocol laboratory testing. If upon further evaluation the
troponin levels do not exhibit a typical rise and fall pattern,
or there is an alternative explanation for the troponin leak
(e.g., cardiac arrest or external defibrillation) that can be
explained by a diagnosis other than myocardial ischemia,
this should not be misconstrued as a myocardial infarction
(as defined by Thygesen et al. [23,25]) based on the
laboratory test alone (23,25,26). In addition, a nonspecific
transient biomarker elevation may also occur in some
situations of cardiac arrest in which there is a low-level rise
in troponin with subsequent fall, in the absence of coronary
artery disease or thrombosis. This also should not be
considered a myocardial infarction without underlying cor-
onary obstruction, as this leak of troponin is likely related to
the arrest itself. These low-level rises in biomarkers should
not preclude ICD implantation, if criteria for implantation
are otherwise met.
New York Heart Association (NYHA)
Functional Classification:
The definitions are included in the table in the following
text. The patient’s NYHA functional classification at the
time of the decision to implant the device should be used
for this classification. If the patient has left ventricular
dysfunction, but no symptoms of heart failure, this should
be coded as “class I.” If the patient is hospitalized for heart
failure at the time the decision is made to implant the
device, the NYHA functional class on optimized GDMT
should be utilized.
NYHA Functional Classification
lass I No limitation of physical activity. Ordinary physical activity does not
cause undue fatigue, palpitation, or dyspnea.
lass II Slight limitation of physical activity. Comfortable at rest. Ordinary
physical activity results in fatigue, palpitation, or dyspnea.
lass III Marked limitation of physical activity. Comfortable at rest. Less
than ordinary activity causes fatigue, palpitation, or dyspnea.
lass IV Unable to carry on any physical activity without discomfort.
Symptoms of heart failure may be present even at rest. If any
physical activity is undertaken, discomfort is increased.
Adapted with permission from the Heart Failure Society of America (27).
Ambulatory NYHA Functional Class IV:
Ambulatory class IV is defined as class IV heart failure
with: 1) no active acute coronary syndrome; 2) no
inotropes; and 3) on GDMT.
Normal Left Ventricular Ejection Fraction:
A normal LVEF is defined as 50%.
Primary Versus Secondary Prevention for ICD (28)
Secondary Prevention (Section 1 Indications):
Secondary prevention refers to an indication for an ICDexclusively for patients who have survived 1 or more cardiac
arrests or sustained ventricular tachycardia. Patients with
cardiac conditions associated with a high risk of sudden
death who have unexplained syncope that is likely to be due
to self-terminating ventricular arrhythmias are also consid-
ered to have a secondary prevention indication.
Primary Prevention (Section 2 Indications):
Primary prevention is an indication for an ICD to prevent
sudden cardiac death. It refers to use of ICDs in individuals
who are at risk for, but have not yet had, an episode of
sustained VT, VF, or cardiac arrest.
QRS Duration:
A “narrow” QRS duration is 120 ms. A wide QRS is
120 ms and may have a left bundle branch block (LBBB),
right bundle branch block (RBBB), or nonspecific intraven-
tricular conduction delay morphology. For the purpose of
this AUC document and for consistency with the focused
update of the device-based therapy guidelines (29), “non-
LBBB” morphology is used to refer to both RBBB and
intraventricular conduction delay morphologies. For the
purpose of CRT implantation, it is assumed that the wide
QRS is present consistently, and does not represent an
intermittent bundle branch block or intermittent QRS
widening, thereby excluding QRS widening that is transient
or rate-related. If there is discrepancy in the measurement of
QRS duration on various electrocardiograms (ECGs), the
most representative ECG obtained proximate to the final
clinical decision-making process will be utilized to deter-
mine candidacy for CRT implantation.
Sudden Cardiac Arrest:
Sudden cardiac arrest is defined as the sudden cessation of
effective cardiac mechanical activity resulting in unrespon-
siveness, without normal breathing or signs of circulation. If
corrective measures are not rapidly taken, this progresses to
sudden death. Cardiac arrest should be used to signify an
event that is reversed, usually by cardiopulmonary resusci-
tation and/or defibrillation, cardioversion, or cardiac pacing.
The mechanism for a tachyarrhythmic arrest may be due to
VT or VF, or VT degenerating into VF.
Syncope:
Syncope is defined as a sudden loss of consciousness with
the inability to maintain postural tone, not related to
anesthesia or a seizure disorder, with spontaneous recovery
reported by the patient or an observer. This excludes cardiac
arrest, which requires resuscitation.
Timing Post-MI:
For the purpose of this AUC document:
• “Acute MI” is defined as 48 h after the onset of
symptoms;
• “Recent post-infarction” is defined as 40 days after
the onset of acute MI symptoms (30,31).
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Generator Replacement:
As part of ICD follow-up care, decisions must be made
regarding the need for generator replacement at the time of
battery depletion. In the absence of contraindications or the
development of new comorbidities that may significantly
limit life expectancy, generator replacement is now typically
recommended for patients who had initial devices im-
planted for primary prevention indications when elective
replacement is reached. However, it is recognized that there
are few long-term data to support this standard of care.
Nonetheless, in addition to assessing for pacemaker depen-
dency, the presence or absence of ICD therapy for ventric-
ular arrhythmias might be taken into account when consid-
ering the need for replacement, particularly if new
comorbidities have developed that may otherwise have an
impact on life expectancy.
Clinically relevant ventricular arrhythmias in an ICD
recipient refer to:
a. VT leading to antitachycardia pacing, or VT/VF
leading to shock therapy, or
b. VT duration 30 s in a monitor-only zone (or 30 s
associated with hemodynamically significant symp-
toms), or
c. VT lasting 30 s at a rate near the tachycardia-
detection threshold but not receiving therapy due to
only intermittent detection.
In the case of antitachycardia pacing therapy for VT, it is
recognized that many of these episodes might terminate
spontaneously if detection is delayed. “Nonsustained VT” is
VT of 30 s that terminates spontaneously before delivery
of device therapy (including either antitachycardia pacing or
shock therapy). It is recognized that implanting physicians
will have a variety of different programming preferences,
and some of these may include a monitor zone or prolonged
detection duration in an attempt to minimize appropriate or
inappropriate therapy for arrhythmias that may terminate
spontaneously (32).
Ventricular Fibrillation:
Ventricular fibrillation is a cardiac arrhythmia arising from
the ventricles that occurs when the heart’s electrical activity
becomes disordered and rapid. VF is not synonymous with
device-defined VF, as the device defines VT and VF solely
based on the programmed heart rate and does not take into
account the morphology of the arrhythmia.
Ventricular Tachycardia:
VT is a cardiac tachyarrhythmia of 3 or more consecutive
complexes in duration emanating from 1 of the ventricles Rwith a rate of 100 beats/min. It can be “sustained” or
“nonsustained.”
Ventricular Tachycardia, Sustained:
Sustained VT is defined as VT lasting 30 s or termi-
nated by cardioversion or pacing before that time.
Ventricular Tachycardia, Hemodynamically Significant:
Hemodynamically significant VT is defined as VT that
results in hypotension or hemodynamically significant
symptoms such as angina, dyspnea, lightheadedness,
pre-syncope, or syncope.
Ventricular Tachycardia, Nonsustained:
Nonsustained VT is defined as 3 or more consecutive
premature ventricular complexes but lasting 30 s and
terminating spontaneously, without associated hemody-
namically significant symptoms, and rate 100 beats/
min.
5. Abbreviations
CAD  coronary artery disease
CIED  cardiovascular implantable electronic device
CRT  cardiac resynchronization therapy
ECG  electrocardiogram
GDMT  guideline-directed medical therapy
HF  heart failure
ICD  implantable cardioverter-defibrillator
LBBB  left bundle branch block
LV  left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association
VAD  ventricular assist device
VF  ventricular fibrillation
VT  ventricular tachycardia
6. Results of Ratings
The final ratings for ICDs and CRT therapy are listed by
indication in Tables 1.1 to 6.5 (indications listed by ratings
re provided as an online appendix). The final score reflects
he median score of the 17 technical panel members and has
een labeled according to the categories of Appropriate
median 7 to 9), May Be Appropriate (median 4 to 6), and
arely Appropriate (median 1 to 3). Of the ratings, 45%
ere rated as Appropriate, 33% were rated May Be Appro-
riate, and 22% were rated Rarely Appropriate (see Online
atings Spreadsheet for more details).
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Section 1: Secondary Prevention ICD
Table 1.1. CAD: VF or Hemodynamically Unstable VT Associated With Acute (<48 h) MI (Newly Diagnosed,
No Prior Assessment of LVEF) (Fig. 1)
Indication Appropriate Use Score (1–9)
Total Revascularization Completed After Cardiac Arrest
LVEF
>50% 36% to 49% <35%
1. ● Single episode VF or polymorphic VT during acute (48 h) MI R (2) R (3) M (4)
2. ● Recurrent VF or polymorphic VT during acute (48 h) MI R (3) R (3) M (5)
3. ● VF or polymorphic VT during acute (48 h) MI
● NSVT 4 days post-MI
● Inducible VT/VF at EPS 4 days after revascularization
M (5) A (7) A (8)
No Revascularization Indicated (i.e., No Significant CAD)
LVEF
>50% 36% to 49% <35%
4. ● Single episode VF or polymorphic VT during acute (48 h) MI R (2) R (3) M (4)
5. ● Recurrent VF or polymorphic VT during acute (48 h) MI R (2) R (3) M (5)
Obstructive CAD With Coronary Anatomy Not Amenable to Revascularization
LVEF
>50% 36% to 49% <35%
6. ● VF or polymorphic VT during acute (48 h) MI
● No EPS done
M (5) M (5) A (7)
A  Appropriate; CAD  coronary artery disease; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NSVT  nonsustained
ventricular tachycardia; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.
Table 1.2. CAD: VF or Hemodynamically Unstable VT <48 h (Acute) Post-Elective Revascularization
Indication Appropriate Use Score (1–9)
LVEF
>50% 36% to 49% <35%
7. ● No evidence for acute coronary occlusion, restenosis, preceding infarct, or other clearly
reversible cause
M (6) M (6) A (7)
A  Appropriate; CAD  coronary artery disease; LVEF  left ventricular ejection fraction; M  May Be Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.
Table 1.3. CAD: VF or Hemodynamically Unstable VT (No Recent MI [<40 Days] Prior to VF/VT and/or
No Recent Revascularization [3 Months] Prior to VF/VT) (Fig. 2)
Indication Appropriate Use Score (1–9)
LVEF
>50% 36% to 49% <35%
8. ● No identifiable transient and completely reversible causes
● No need for revascularization identified by cath performed following VF/VT
A (9) A (9) A (9)
9. ● No revascularization performed (significant CAD present at cath performed following VF/VT,
but coronary anatomy not amenable to revascularization)
A (9) A (9) A (9)
10. ● Significant CAD identified at cath performed following VF/VT
● Complete revascularization performed after cardiac arrest
M (5) A (7) A (7)
11. ● Significant CAD identified at cath performed following VF/VT
● Incomplete revascularization performed after cardiac arrest
A (7) A (8) A (9)
A  Appropriate; CAD  coronary artery disease; cath  catheterization; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; VF  ventricular fibrillation;
VT  ventricular tachycardia.
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Indication Appropriate Use Score (1–9)
LVEF
>50% 36% to 49% 35%
12. ● No revascularization performed (significant CAD present at cath performed following VF/VT,
but coronary anatomy not amenable to revascularization)
A (9) A (9) A (9)
13. ● Significant CAD identified at cath performed following VF/VT
● Complete revascularization performed after cardiac arrest
M (5) M (6) A (7)
14. ● Significant CAD identified at cath performed following VF/VT
● Incomplete revascularization performed after cardiac arrest
A (7) A (7) A (8)A  Appropriate; CAD  coronary artery disease; cath  catheterization; LVEF  left ventricular ejection fraction; M  May Be Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.Table 1.5. No CAD: VF or Hemodynamically Unstable VT (Fig. 3)
Indication Appropriate Use Score (1–9)
LVEF
>50% 36% to 49% <35%
15. ● Dilated nonischemic cardiomyopathy A (9) A (9) A (9)
16. ● VT/VF associated with cocaine abuse R (3) M (4) M (5)
Severe Valvular Disease
VT/VF <48 h After Surgical Repair or Replacement of Aortic or Mitral Valve
17. ● No evidence of post-operative valvular dysfunction M (5) M (6) M (6)
VF/Hemodynamically Unstable VT Associated With Other Structural Heart Disease
18. ● Myocardial sarcoidosis A (9)
19. ● Myocarditis; not giant cell myocarditis M (5)
20. ● Giant cell myocarditis A (8)
21. ● Takotsubo cardiomyopathy (stress-induced cardiomyopathy, apical ballooning syndrome)
● 48 h of onset of symptoms
M (5)A  Appropriate; CAD  coronary artery disease; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.Table 1.6. Genetic Diseases with Sustained VT/VF* (Fig. 3)
Indication
Appropriate Use
Score (1–9)
22. ● Congenital long QT A (9)
23. ● Short QT A (9)
24. ● Catecholaminergic polymorphic VT A (9)
25. ● Brugada syndrome A (9)
26. ● ARVC with successful ablation of all inducible monomorphic VTs A (9)
27. ● ARVC with unsuccessful attempt to ablate an inducible VT A (9)
28. ● ARVC without attempted ablation A (9)
29. ● Hypertrophic cardiomyopathy A (9)*Patients with genetic diseases are assumed to have normal LV and RV function, unless otherwise specified.
A  Appropriate; ARVC  arrhythmogenic right ventricular cardiomyopathy; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Indication
Appropriate Use
Score (1–9)
Pharmacologically Induced Sustained VT/VF
30. ● Non-torsades de pointes VT/VF in the setting of antiarrhythmic drug use R (3)
31. ● Drug-induced torsades de pointes R (2)
Idiopathic VF With Normal Ventricular Function
32. ● No family history of sudden cardiac death A (9)
33. ● First degree relative with sudden cardiac death A (9)
Other Causes
34. ● Bradycardia dependent VT/VF M (5)
35. ● WPW syndrome with VT/VF
● Pathway successfully ablated
● Structurally normal heart
R (2)A  Appropriate; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia; WPW  Wolff-Parkinson-White.Table 1.8.1. Syncope in Patients Without Structural Heart Disease* (Fig. 5)
Indication
Appropriate Use
Score (1–9)
Unexplained Syncope With No Structural Heart Disease or Genetically Transmitted Ventricular Arrhythmias
36. ● Normal ECG and structurally normal heart
● Family history of sudden death
R (3)
37. ● Normal ECG and structurally normal heart
● No known family history of sudden death
R (1)
Unexplained Syncope in a Patient With RV or LV Outflow Tract Tachycardia (Idiopathic VT) With Normal LV and RV Function and Anatomy
38. ● Documented sustained monomorphic VT (LBBB/inferior axis) at the time of syncope
● Ablation not yet attempted
R (2)
39. ● Documented history of sustained monomorphic VT (LBBB/inferior axis) but not recorded at the time of syncope
● Ablation not yet attempted
R (2)
40. ● Documented sustained monomorphic VT (LBBB/inferior axis) at the time of syncope
● Ablation successful
R (2)
Unexplained Syncope in a Patient With Long QT Syndrome
41. ● While on treatment with beta blockers A (9)
42. ● Not being treated with beta blockers A (7)
Unexplained Syncope in a Patient With Brugada ECG Pattern
43. ● No EPS performed A (8)
44. ● EPS performed
● No ventricular arrhythmias induced
A (8)
45. ● EPS performed
● Sustained VT/VF induced
A (9)
Unexplained Syncope in a Patient With Catecholaminergic Polymorphic VT
46. ● While on treatment with beta blockers A (8)
47. ● Not being treated with beta blockers A (8)
*It is assumed that an EPS was not performed unless otherwise specified.
A  Appropriate; ECG  electrocardiogram; EPS  electrophysiological study; LBBB  left bundle branch block; LV  left ventricular; R  Rarely Appropriate; RV  right ventricular; VF  ventricular
fibrillation; VT  ventricular tachycardia.
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Indication
Appropriate Use
Score (1–9)
Unexplained Syncope With Coronary Heart Disease and No Acute MI
LVEF >50%
48. ● Electrophysiology study and noninvasive investigations failed to define a cause of syncope
● No prior MI
● Nonobstructive CAD; revascularization not indicated
R (2)
49. ● Electrophysiology study and noninvasive investigations failed to define a cause of syncope
● No prior MI
● Obstructive CAD; not amenable to revascularization
R (3)
Unexplained Syncope With Prior MI and No Acute MI
LVEF 36% to 49%
50. ● Electrophysiology study failed to define a cause of syncope
● Nonobstructive CAD; revascularization not indicated
M (5)
51. ● Electrophysiology study failed to define a cause of syncope
● Obstructive CAD; not amenable to revascularization
M (6)
52. ● Electrophysiology study revealed inducible sustained VT/VF A (9)
Unexplained Syncope With Prior MI and No Acute MI
LVEF <35%
53. ● EPS not performed A (9)
54. ● Inducible VT/VF at EPS A (9)
55. ● Not inducible at EPS A (8)A Appropriate; CAD  coronary artery disease; EPS electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI myocardial infarction; R  Rarely Appropriate;
VF  ventricular fibrillation; VT  ventricular tachycardia.Table 1.8.3. Syncope in Patients With Nonischemic Structural Heart Disease (Fig. 7)
Indication Appropriate Use Score (1–9)
Unexplained Syncope in a Patient With Left Ventricular Hypertrophy Without Criteria for Hypertrophic Cardiomyopathy
LVEF
>50%* 36% to 49% <35%
56. ● Left ventricular hypertrophy/hypertensive heart disease R (3) M (5) A (8)
Unexplained Syncope in a Patient With Nonischemic Cardiomyopathy
LVEF
>50%* 36% to 49% <35%
57. ● Nonischemic dilated cardiomyopathy M (4) M (6) A (8)
58. ● Left ventricular non-compaction M (6) A (7) A (8)
59. ● Hypertrophic cardiomyopathy A (8)
60. ● Cardiac amyloidosis M (6)
61. ● Tetralogy of Fallot with prior corrective surgery A (7)
Unexplained Syncope in a Patient With Arrhythmogenic Right Ventricular Cardiomyopathy
62. ● No EPS performed A (7)
63. ● No inducible VT/VF at EPS A (7)
64. ● Inducible VT/VF at EPS
● All inducible VTs successfully ablated
A (7)
65. ● Inducible VT/VF at EPS
● Ablation unsuccessful
A (8)*LVEF preserved on medical therapy
A  Appropriate; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Table 1.9. Sustained Hemodynamically Stable Monomorphic VT Associated With Structural Heart Disease (Fig. 8)
Indication Appropriate Use Score (1–9)
LVEF
>50%* 36% to 49% <35%
66. ● CAD and prior MI A (7) A (7) A (9)
67. ● CAD and prior MI
● All inducible VTs successfully ablated
M (6) M (6) A (9)
68. ● CAD and prior MI
● Troponin elevation thought to be secondary to VT
● All inducible VTs successfully ablated
M (5) A (7) A (8)
69. ● Nonischemic dilated cardiomyopathy A (7) A (7) A (9)
70. ● Nonischemic dilated cardiomyopathy
● All inducible VTs successfully ablated
M (5) A (7) A (8)
71. ● Bundle branch re-entry successfully ablated in a patient with nonischemic cardiomyopathy M (4) A (7) A (8)
*LVEF preserved on medical therapy
A Appropriate; CAD coronary artery disease; LVEF left ventricular ejection fraction; MMay Be Appropriate; MImyocardial infarction; VF ventricular fibrillation; VT ventricular tachycardia.
Table 2.1.1. Post-Acute Myocardial Infarction (<40 Days) LVEF <30% (Fig. 9)
Indication
Appropriate Use
Score (1–9)
Plan for Revascularization (Not Yet Performed)
72. ● No NSVT R (2)
Revascularized After Acute MI
73. ● No NSVT R (2)
74. ● Asymptomatic NSVT (4 days post MI)
● No EPS performed
R (3)
75. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed after revascularization, within 30 days of MI)
A (7)
76. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed after revascularization, between 30 and 40 days after MI)
A (8)
77. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed after revascularization, within 30 days after MI)
R (3)
78. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed after revascularization, between 30 and 40 days after MI)
M (4)
Not Revascularized
Obstructive CAD With Coronary Anatomy Not Amenable to Revascularization
79. ● No NSVT R (2)
80. ● Asymptomatic NSVT (4 days post MI)
● No EPS performed
M (4)
81. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed within 30 days of MI)
A (7)
82. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed between 30 and 40 days after MI)
A (8)
83. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed within 30 days of MI)
M (4)
84. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed between 30 and 40 days after MI)
M (4)
A  Appropriate; CAD  coronary artery disease; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NSVT  nonsustained
ventricular tachycardia; R  Rarely Appropriate; VT  ventricular tachycardia.
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Indication
Appropriate Use
Score (1–9)
Revascularized for Acute MI
85. ● No NSVT R (2)
86. ● Asymptomatic NSVT (4 days post MI)
● No EPS performed
R (3)
87. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed after revascularization, within 30 days of MI)
A (7)
88. ● Asymptomatic NSVT (4 days post MI)
● EPS with inducible sustained VT (EPS performed after revascularization, between 30 and 40 days after MI)
A (7)
89. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed after revascularization, within 30 days of MI)
R (3)
90. ● Asymptomatic NSVT (4 days post MI)
● EPS without inducible VT (EPS performed after revascularization, between 30 and 40 days after MI)
R (3)A  Appropriate; CAD  coronary artery disease; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; MI  myocardial infarction; NSVT  nonsustained ventricular tachycardia;
 Rarely Appropriate; VT  ventricular tachycardia.Table 2.1.3. Post-Acute MI (<40 Days) and Pre-Existing Chronic Cardiomyopathy (>3 Months)
Indication
Appropriate Use
Score (1–9)
91. ● LVEF 30% due to old infarction
● NYHA class I
A (8)
92. ● LVEF 35% due to old infarction
● NYHA class II–III
A (9)
93. ● LVEF 35% due to nonischemic causes
● NYHA class II–III
A (8)A  Appropriate; LVEF  left ventricular ejection fraction; MI  myocardial infarction; NYHA  New York Heart Association.Table 2.1.4. Post-MI (<40 Days) and Need for Guideline-Directed Pacemaker Therapy Post-MI (e.g., SSS, CHB, or
Other Indications for Permanent Pacemaker)
Indication
Appropriate Use
Score (1–9)
94. ● LVEF 35% A (7)
95. ● LVEF 36% to 40% M (6)A  Appropriate; CHB  complete heart block; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; SSS  sick sinus syndrome.
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Indication Appropriate Use Score (1–9)
No Recent PCI or CABG (<3 Months)
NYHA Class
I II III IV
96. ● LVEF 30% A (8) A (9) A (9)
97. ● LVEF 31% to 35% A (7) A (9) A (9)
98. ● LVEF 36% to 40%
● Asymptomatic NSVT
● No EPS
M (5)
99. ● LVEF 36% to 40%
● Asymptomatic NSVT
● EPS without inducible VT/VF
M (5)
100. ● LVEF 36% to 40%
● Asymptomatic NSVT
● EPS with inducible sustained VT/VF
A (8)
Recent PCI or CABG (<3 Months)
101. ● No known pre-existing cardiomyopathy
● LVEF 35%
M (6)
102. ● Pre-existing documented cardiomyopathy
● LVEF 35% on guideline-directed medical therapy 3 months before PCI/CABG
A (8)
103. ● LVEF 35%
● Need for ppm post-revascularization (e.g., SSS, CHB, or other guideline-directed indications for permanent
pacemaker)
A (8)
104. ● LVEF 36%–40%
● Need for ppm post-revascularization (e.g., SSS, CHB, or other guideline-directed indications for permanent
pacemaker)
M (6)
NOTE: grey shaded boxes indicate “not rated.”
A  Appropriate; CABG  coronary artery bypass graft surgery; CHB  complete heart block; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate;MI  myocardial infarction; NSVT  nonsustained ventricular tachycardia; NYHA  New York Heart Association; PCI  percutaneous coronary intervention; PPM  permanent pacemaker; SSS  sick
sinus syndrome; VF  ventricular fibrillation; VT  ventricular tachycardia.Table 2.3. Duration of Guideline-Directed Medical Therapy for Ischemic Cardiomyopathy Without Recent MI
(Revascularization Not Indicated)
Indication
Appropriate Use
Score (1–9)
105. ● LVEF 35%
● On guideline-directed medical therapy for 3 months
M (5)
106. ● LVEF 35%
● On guideline-directed medical therapy 3 months
● NSVT
● EPS with inducible sustained VT
A (8)
107. ● LVEF 35%
● On guideline-directed medical therapy 3 months
A (9)A  Appropriate; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NSVT  nonsustained ventricular tachycardia; VT 
ventricular tachycardia.
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Indication Appropriate Use Score (1–9)
Treatment Since Diagnosis <3 Months
Newly Diagnosed Cardiomyopathy With Narrow QRS
NYHA Class
I II–III IV
108. ● LVEF 30% R (3) M (4)
109. ● LVEF 31% to 35% R (3) R (3)
At Least 3 Months on Guideline-Directed Medical Therapy
NYHA Class
I II–III IV
110. ● LVEF 30% A (7) A (9)
111. ● LVEF 31% to 35% A (7) A (9)
112. ● LVEF 36% to 40% M (4)
Recent Valve Surgery (i.e., Same Hospitalization or <3 Months) Which Included Incidental Bypass Graft
113. ● LVEF 35%
● Need for pacemaker and LV function not felt likely to improve
A (7)
Specific Etiologies
LVEF
35% 35%
114. ● Sarcoid heart disease A (8) M (6)
115. ● Myotonic dystrophy A (8) M (5)
116. ● Chagas disease A (8) M (6)
117. ● Amyloidosis with heart failure M (6) M (5)
118. ● Acute lymphocytic myocarditis
● Newly diagnosed (3 months ago)
R (3) R (3)
119. ● Giant cell myocarditis A (8) A (7)
120. ● Peripartum cardiomyopathy
● Persists 3 months postpartum
A (8) M (4)NOTE: grey shaded boxes indicate “not rated.”
A  Appropriate; LV  left ventricular; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NYHA  New York Heart Association; R  Rarely Appropriate.Table 2.5. Genetic Conditions (Excludes Syncope and Sustained VT, Covered in Section 1) (Fig. 13)
Indication
Appropriate Use
Score (1–9)
121. ● Hypertrophic cardiomyopathy with 1 or more risk factors A (7)
122. ● Arrhythmogenic right ventricular dysplasia/cardiomyopathy with no symptoms due to arrhythmia A (7)
Congenital Long QT Syndrome With 1 or More Risk Factors
123. ● Not receiving guideline-directed medical therapy M (6)
124. ● Receiving guideline-directed medical therapy A (7)
Catecholaminergic Polymorphic VT With Nonsustained VT (Without Syncope)
125. ● Not receiving beta-blockers, flecainide, or propafenone A (7)
126. ● Receiving beta-blockers A (7)
127. ● Not tolerating or breakthrough nonsustained ventricular arrhythmias on beta-blockers A (8)
Incidentally Discovered Brugada by ECG (Type I ECG Pattern) In the Absence of Symptoms or Family History of Sudden Cardiac Death
128. ● No EPS R (3)
129. ● Inducible VT or VF at EPS A (7)
130. ● No inducible VT or VF at EPS R (3)
Familial Dilated/Nonischemic Cardiomyopathy (RV/LV) Associated With Sudden Cardiac Death
131. ● Evidence of structural cardiac disease but LVEF 35% A (7)
132. ● Normal ECG and echo but carrying the implicated gene M (6)
133. ● LV non-compaction with LVEF 35% A (7)A  Appropriate; ECG  electrocardiogram; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate; RV  right ventricular; VF 
ventricular fibrillation; VT  ventricular tachycardia.
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It should be noted that the scenarios in this section refer to ICDs implanted for primary prevention.
Table 3.1. Special Conditions/Comorbidities in Patients for Primary Prevention (Meeting Indications of ICD Implant Related to
HF Diagnosis With LVEF <30% on Guideline-Directed Medical Therapy >3 Months) (Fig. 14)
Indication
Appropriate Use
Score (1–9)
Life Expectancy
134. ● Life expectancy 1 year from cardiac or noncardiac conditions R (1)
135. ● Noncardiac disease with life expectancy 1 to 2 years M (4)
Elderly
NYHA Class
I II III IV
136. ● 80 to 89 years old M (4) M (5) M (5)
137. ● 90 years old R (3) M (4) M (4)
Cognitive Impairment
138. ● Not able to understand or provide informed consent
● Health care proxy consents to ICD
M (4)
139. ● Not able to understand or provide informed consent
● No health care proxy can be identified
R (3)
Advanced Psychiatric Impairment
140. ● Significant psychiatric illnesses that may be aggravated by device implantation or that may
preclude regular follow-up
R (1)
Renal Disease
NYHA Class
I II III IV
141. ● Severe symptomatic peripheral vascular disease (e.g., peripheral interventions or
clinical claudication)
M (6) A (7) A (7)
142. ● Chronic kidney disease on dialysis
● Not a candidate for renal transplant
M (5) M (6) M (6)
143. ● Chronic kidney disease with CrCl 30 ml, not yet on dialysis but candidate for dialysis M (6) M (6) M (6)
Other Comorbidities
144. ● IV drug abuse (ongoing) R (2)
145. ● Unresolved infection associated with risk for hematogenous seeding R (2)
146. ● Noncompliance with medical therapy and follow-up R (3)
Class IV Heart Failure
147. ● On waiting list for heart transplant A (8)
148. ● Not candidate for cardiac transplantation, CRT, or VAD
● Refractory symptoms on oral therapy
R (2)
149. ● Patient with a VAD M (6)
150. ● Not a candidate for transplant or VAD
● Does not meet CRT criteria
● Planned outpatient continuous intravenous inotropic therapy for palliation
R (2)
NOTE: grey shaded boxes indicate “not rated.”
A Appropriate; CrCl creatinine clearance; CRT cardiac resynchronization therapy; HF heart failure; ICD implantable cardioverter-defibrillator; IV intravenous; LVEF left ventricular ejection
raction; M  May Be Appropriate; NYHA  New York Heart Association; R  Rarely Appropriate; RV  right ventricular; VAD  ventricular assist device; VT  ventricular tachycardia.
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Table 4.1. Primary Prevention ICD at Initial Implant
Indication
Appropriate Use
Score (1–9)
No Clinically Relevant Ventricular Arrhythmias on ICD Since Implant
151. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now unchanged
A (8)
152. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now 36% to 49%
M (6)
153. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now 50% (normalized)
M (5)
No Clinically Relevant Ventricular Arrhythmias on ICD Since Implant (Now Has Prognosis <1 Year)
Replace
With ICD
Replace With
Pacemaker
154. ● Patient received primary prevention ICD
● Pacemaker dependent
M (4) A (8)
155. ● Patient received primary prevention ICD
● Not pacemaker dependent
R (2)
Clinically Relevant Ventricular Arrhythmias on ICD Since Implant
156. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now unchanged
A (9)
157. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now 36% to 49%
A (8)
158. ● Patient received primary prevention ICD when LVEF was 35%
● LVEF now 50% (normalized)
A (8)
159. ● Patient received primary prevention ICD
● Now has prognosis 1 year
M (5)
A  Appropriate; ICD  implantable cardioverter-defibrillator; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate.
Table 4.2. Secondary Prevention ICD at Initial Implant
Indication
Appropriate Use
Score (1–9)
160. ● Patient received secondary prevention ICD
● No ventricular arrhythmia since initial implant
A (8)
161. ● Patient received secondary prevention ICD
● Had ventricular tachyarrhythmias in the monitor zone lasting 30 s, but no treated ventricular arrhythmias since initial
implant
A (9)
162. ● Patient received secondary prevention ICD
● Had ventricular arrhythmias receiving ICD therapy since implant
A (9)
A  Appropriate; ICD  implantable cardioverter-defibrillator.
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In this section, symptoms refer to those potentially related to bradycardia such as lightheadedness, pre-syncope, loss of
consciousness, fatigue, or reduced exercise tolerance. All listed scenarios are asymptomatic unless otherwise specified. For
scenarios where the QRS is wide, it is assumed that the patient does not otherwise meet criteria for CRT implantation.
Table 4.3. Primary Prevention at Initial Implant: Replacement of CRT-ICD for ERI
Indication
Appropriate Use
Score (1–9)
Primary Prevention at Initial Implant: Replacement of CRT-ICD for ERI
Replace
With CRT-
ICD
Replace With
CRT-Pacemaker
163. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now unchanged (despite clinical improvement)
A (9) R (3)
164. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now 36% to 49%
A (8) M (5)
165. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now 50% (normalized)
A (7) M (6)
A  Appropriate; CRT  cardiac resynchronization therapy; ERI  elective replacement indicator; ICD  implantable cardioverter-defibrillator; LVEF  left ventricular ejection fraction; M  May Be
ppropriate; R  Rarely Appropriate.
Table 4.4. Secondary Prevention at Initial Implant: Replacement of CRT-ICD for ERI
Indication
Appropriate Use Score
(1–9)
Secondary Prevention at Initial Implant: Replacement of CRT-ICD for ERI
Replace
With CRT-
ICD
Replace With
CRT-Pacemaker
166. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now unchanged (despite clinical improvement)
A (9)
167. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now 36% to 49%
A (9) R (3)
168. ● Patient received a CRT-ICD when LVEF was 35%
● LVEF now 50% (normalized)
A (8) R (3)
NOTE: grey shaded box indicates “not rated.”
A  Appropriate; CRT  cardiac resynchronization therapy; ERI  elective replacement indicator; ICD  implantable cardioverter-defibrillator; LVEF  left ventricular ejection fraction; R  Rarely
Appropriate.
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Indication
Appropriate Use
Score (1–9)
Conduction System Abnormalities
Sinus Node Dysfunction Who Meets Criteria for ICD
169. ● Sinus node dysfunction (includes sinus pauses, chronotropic incompetence, or marked sinus bradycardia
that results from drug therapy required to treat other conditions)
● Symptomatic
A (9)
170. ● Resting sinus bradycardia (resting heart rate 50 beats/min)
● Asymptomatic
A (7)
Conduction System Abnormalities
AV Conduction Disease Who Meets Criteria for ICD (Narrow QRS <120 ms)
171. ● Third-degree AV block or advanced second-degree AV block (Mobitz II AV block or high-degree AV block)
● Symptomatic
● CRT not indicted
A (9)
172. ● Third-degree AV block or advanced second-degree AV block (Mobitz II AV block or high-degree AV block)
● Asymptomatic
● CRT not indicated
A (8)
173. ● Mobitz Type I AV block
● Asymptomatic
● CRT not indicated
M (6)
174. ● First-degree AV block (PR 300 ms)
● Asymptomatic
M (5)
175. ● First-degree AV block (PR 300 ms)
● Asymptomatic
M (6)
Conduction System Abnormalities
Bundle Branch Block
176. ● Sinus rhythm with normal PR interval
● LBBB
● CRT not indicated
M (5)
177. ● Sinus rhythm with first-degree AV block
● LBBB
● CRT not indicated
M (6)
178. ● Sinus rhythm with normal PR interval
● Bifascicular block (RBBB/LAFB or RBBB/LPFB)
● CRT not indicated
M (5)
179. ● Sinus rhythm with first-degree AV block
● Bifascicular block (RBBB/LAFB or RBBB/LPFB)
● CRT not indicated
M (6)
180. ● Alternating RBBB and LBBB
● CRT not indicated
A (8)
Conduction System Abnormalities
Acute MI or Ischemic Event
Narrow QRS
(<120 ms)
Chronic Wide
QRS (>120 ms)
181. ● Transient AV block thought to be secondary to ischemia
● Status post successful revascularization
M (5) A (7)
182. ● Transient AV block thought to be secondary to ischemia
● Not amenable to revascularization
M (6) A (7)
Conduction System Abnormalities
Cardiac Valve Surgery
183. ● Transient AV block
● Narrow QRS (120 ms)
M (5)
184. ● New LBBB and first-degree AV block A (7)A  Appropriate; AV  atrioventricular; CRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator; LAFB  left anterior fascicular block; LBBB  left bundle branch block;
PFB  left posterior fascicular block; M  May Be Appropriate; MI  myocardial infarction; R  Rarely Appropriate; RBBB  right bundle branch block.
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Indication
Appropriate Use
Score (1–9)
Meets Criteria for ICD (Narrow QRS <120 ms)
185. ● Sinus rhythm with normal PR interval
● Asymptomatic
M (4)ICD  implantable cardioverter-defibrillator; M  May Be Appropriate.Table 5.3. Tachyarrhythmias
Indication
Appropriate Use
Score (1–9)
Atrial Arrhythmias or “Supraventricular Tachycardia (SVT)” and “No Standard Pacing Indications”*
186. ● Paroxysmal atrial arrhythmias A (7)
187. ● Underlying structural heart disease (e.g., ischemic or nonischemic CM)
● No known paroxysmal atrial arrhythmias or SVT
M (5)
188. ● Structurally normal heart
● No known paroxysmal atrial arrhythmias or SVT
M (4)
189. ● Long-standing persistent or permanent atrial fibrillation or atrial flutter
● No plans for cardioversion or rhythm control
R (1)
Known Slow Ventricular Arrhythmias
190. ● Active patient
● Known “slow VT” that overlaps with sinus tachycardia rate
A (8)*Use of dual-chamber device for theoretical benefit related to arrhythmia discrimination (SVT vs. VT detection enhancements).
A  Appropriate; CM  cardiomyopathy; M  May Be Appropriate; R  Rarely Appropriate; SVT  supraventricular tachycardia; VT  ventricular tachycardia.Table 5.4. Other Disorders
Indication
Appropriate Use
Score (1–9)
Genetic Disorders*
191. ● Congenital long QT syndrome
● ICD for secondary prevention
A (7)
192. ● Congenital long QT syndrome
● ICD for primary prevention
A (7)
193. ● Hypertrophic cardiomyopathy
● Narrow QRS (120 ms)
● No standard bradycardia pacing indications
M (6)
194. ● Hypertrophic cardiomyopathy
● Wide QRS (120 ms)
● No standard bradycardia pacing indications
M (6)*Use of dual-chamber device for theoretical benefit related to arrhythmia discrimination (SVT vs. VT detection enhancements) and pacing to reduce the development of ventricular arrhythmias.
A  Appropriate; ICD  implantable cardioverter-defibrillator; M  May Be Appropriate; SVT  supraventricular tachycardia; VT  ventricular tachycardia.
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Non-LBBB is defined as RBBB or nonspecific intraventricular conduction block (not transient or rate-related).
Table 6.1. Ischemic Cardiomyopathy (Fig. 15)
Indication Appropriate Use Score (1–9)
LVEF <30%, Ischemic Cardiomyopathy
NYHA Class
I II III-amb IV
195. ● QRS 120 ms
● Sinus rhythm
R (1) R (1) R (1)
196. ● QRS 120–149 ms
● LBBB
● Sinus rhythm
M (5) A (7) A (8)
197. ● QRS 150 ms
● LBBB
● Sinus rhythm
A (7) A (8) A (9)
198. ● QRS 120–149 ms
● Non-LBBB
● Sinus rhythm
R (3) R (3) M (6)
199. ● QRS 150 ms
● Non-LBBB
● Sinus rhythm
M (4) M (6) A (7)
LVEF 31% to 35%, Ischemic Cardiomyopathy
NYHA Class
I II III-amb IV
200. ● QRS 120 ms
● Sinus rhythm
R (1) R (1) R (1)
201. ● QRS 120–149 ms
● LBBB
● Sinus rhythm
M (5) A (7) A (8)
202. ● QRS 150 ms
● LBBB
● Sinus rhythm
M (6) A (8) A (9)
203. ● QRS 120–149 ms
● Non-LBBB
● Sinus rhythm
R (3) R (3) M (6)
204. ● QRS 150 ms
● Non-LBBB
● Sinus rhythm
M (4) M (6) A (7)
A  Appropriate; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appropriate; NYHA  New York Heart Association; R  Rarely Appropriate.
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Indication Appropriate Use Score (1–9)
LVEF <30%, Nonischemic Cardiomyopathy
NYHA Class
I II III-amb IV
205. ● QRS 120 ms
● Sinus rhythm
R (1) R (1) R (1)
206. ● QRS 120-149 ms
● LBBB
● Sinus rhythm
M (4) A (7) A (8)
207. ● QRS 150 ms
● LBBB
● Sinus rhythm
M (6) A (9) A (9)
208. ● QRS 120-149 ms
● Non-LBBB
● Sinus rhythm
R (3) R (3) M (6)
209. ● QRS 150 ms
● Non-LBBB
● Sinus rhythm
M (5) M (6) A (8)
LVEF 31% to 35%, Nonischemic Cardiomyopathy
NYHA Class
I II III-amb IV
210. ● QRS 120 ms
● Sinus rhythm
R (1) R (1) R (1)
211. ● QRS 120–149 ms
● LBBB
● Sinus rhythm
M (5) A (7) A (8)
212. ● QRS 150 ms
● LBBB
● Sinus rhythm
M (6) A (8) A (9)
213. ● QRS 120–149 ms
● Non-LBBB
● Sinus rhythm
R (3) R (3) M (6)
214. ● QRS 150 ms
● Non-LBBB
● Sinus rhythm
M (5) M (6) A (7)A  Appropriate; amb  ambulatory; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appropriate; NYHA  New York Heart Association; R  Rarely Appropriate.Table 6.3.1. LVEF >35% of Any Etiology (ICD Indicated) (Fig. 17)
Indication
Appropriate Use Score
(1–9)
NYHA Class
I-II III-amb IV
215. ● QRS 120 ms
● Sinus rhythm
R (1) R (1)
216. ● QRS 120–149 ms
● LBBB
● Sinus rhythm
R (3) M (4)
217. ● QRS 150 ms
● LBBB
● Sinus rhythm
M (4) M (5)
218. ● QRS 120–149 ms
● Non-LBBB
● Sinus rhythm
R (2) R (3)
219. ● QRS 150 ms
● Non-LBBB
● Sinus rhythm
R (3) M (4)Amb ambulatory; ICD implantable cardioverter-defibrillator; LBBB left bundle branch block; LVEF left ventricular ejection fraction; MMay Be Appropriate; NYHA New York Heart Association;
 Rarely Appropriate.
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Indication
Appropriate Use
Score (1–9)
NYHA Class IV on Intravenous Inotropic Support
220. ● QRS 120–149 ms
● LBBB
M (6)
221. ● QRS 150 ms
● LBBB
M (6)
222. ● QRS 120–149 ms
● Non-LBBB
M (4)
223. ● QRS 150 ms
● Non-LBBB
M (5)LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appropriate; NYHA  New York Heart Association.Table 6.4. Pre-Existing or Anticipated RV Pacing With a Clinical Indication for ICD or Pacemaker Implantation (Fig. 19)
Indication
Appropriate Use Score
(1–9)
Intrinsic Narrow QRS, LVEF <35%
NYHA Class
I-II III-amb IV
224. ● RV pacing anticipated 40% M (4) M (5)
225. ● RV pacing anticipated 40% A (7) A (8)
Intrinsic Narrow QRS, LVEF >35%
NYHA Class
I-II III-amb IV
226. ● RV pacing anticipated 40% R (2) M (4)
227. ● RV pacing anticipated 40% M (5) M (6)A  Appropriate; amb  ambulatory; ICD  implantable cardioverter-defibrillator; LVEF  left ventricular ejection fraction; M  May Be Appropriate; NYHA  New York Heart Association; R  Rarely
Appropriate; RV  right ventricular.Table 6.5. Refractory Class III/IV HF <3 Months Post-Revascularization and/or <40 Days Post-MI (Fig. 20)
Indication
Appropriate Use
Score (1–9)
No Other Indication for Ventricular Pacing, LVEF <35%
228. ● QRS 120–149 ms
● LBBB
A (7)
229. ● QRS 150 ms
● LBBB
A (8)
230. ● QRS 120–149 ms
● Non-LBBB
M (5)
231. ● QRS 150 ms
● Non-LBBB
A (7)
No Other Indication for Ventricular Pacing, LVEF 36% to 50%
232. ● QRS 120–149 ms
● LBBB
R (3)
233. ● QRS 150 ms
● LBBB
M (4)
234. ● QRS 120–149 ms
● Non-LBBB
R (3)
235. ● QRS 150 ms
● Non-LBBB
R (3)A  Appropriate; HF  heart failure; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; R  Rarely Appropriate; RV right ventricular.
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Figure 1. Secondary Prevention: CAD—VF or Hemodynamically Unstable VT Associated With Acute (<48 h) MI
Indication 3 for nonsustained VT 4 days post-MI and inducible VT/VF at EPS 4 days after revascularization is not represented in this figure and was rated as Appropriate
for LVEF 50% and May Be Appropriate for LVEF 50%.
A  Appropriate; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; R  Rarely Appropriate;
VF  ventricular fibrillation; VT  ventricular tachycardia.
Figure 2. Secondary Prevention: VF or Hemodynamically Unstable VT With No Recent MI and/or No Recent Revascularization
A  Appropriate; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Disorders
A  Appropriate; ARVC  arrhythmogenic right ventricular cardiomyopathy; CM  cardiomyopathy; CMVT  catecholaminergic polymorphic ventricular tachycardia; EPS 
electrophysiological study; HCM  hypertrophic cardiomyopathy; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NICM  non-
ischemic cardiomyopathy; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.Figure 4. Secondary Prevention: No Structural Heart Disease (LVEF >50%) or Known Genetic Causes of Sustained VT/VF
A  Appropriate; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia; WPW 
Wolff-Parkinson-White.
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March 26, 2013:1318–68 Appropriate Use Criteria for ICD/CRTFigure 5. Secondary Prevention: Syncope in Patients Without Structural Heart DiseaseA  Appropriate; ECG  electrocardiogram; LV  left ventricular; LVEF  left ventricular ejection fraction; R  Rarely Appropriate; RV  right ventricular; VF  ventricular
fibrillation; VT  ventricular tachycardia.Figure 6. Secondary Prevention: Syncope in Patients With Coronary Artery Disease
A  Appropriate; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; R  Rarely Appropriate;
VF  ventricular fibrillation; VT  ventricular tachycardia.
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Appropriate Use Criteria for ICD/CRT March 26, 2013:1318–68Figure 7. Secondary Prevention: Syncope in Patients with Nonischemic Structural Heart DiseaseA  Appropriate; CM  cardiomyopathy; HCM  hypertrophic cardiomyopathy; LV  left ventricular; LVEF  left ventricular ejection fraction; M  May Be Appropriate;
NIDCM  nonischemic dilated cardiomyopathy; R  Rarely Appropriate.Figure 8. Secondary Prevention: Sustained Hemodynamically Stable Monomorphic VT Associated With Structural Heart Disease
A  Appropriate; CAD  coronary artery disease; CM  cardiomyopathy; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate;
MI  myocardial infarction; NICM  nonischemic cardiomyopathy; VT  ventricular tachycardia.
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A  Appropriate; EP  electrophysiological; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction;
NSVT  nonsustained ventricular tachycardia; R  Rarely Appropriate; VF  ventricular fibrillation; VT  ventricular tachycardia.Figure 10. Primary Prevention: Coronary Artery Disease, Prior MI (>40 Days) With Ischemic Cardiomyopathy
A  Appropriate; CABG  coronary artery bypass graft; CM  cardiomyopathy; EPS  electrophysiological study; LVEF  left ventricular ejection fraction; M  May Be Appro-
priate; MI  myocardial infarction; NSVT  nonsustained ventricular tachycardia; NYHA  New York Heart Association; PCI  percutaneous coronary intervention; ppm 
permanent pacemaker; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Appropriate Use Criteria for ICD/CRT March 26, 2013:1318–68Figure 11. Primary Prevention: Nonischemic CardiomyopathyA  Appropriate; CM  cardiomyopathy; dx  diagnosis; GDMT  guideline-directed medical therapy; LVEF  left ventricular ejection fraction; M  May Be Appropriate;
NYHA  New York Heart Association; R  Rarely Appropriate.Figure 12. Primary Prevention: Nonischemic Cardiomyopathy, Specific EtiologiesA  Appropriate; CM  cardiomyopathy; LVEF  left ventricular ejection fraction; M  May Be Appropriate; R  Rarely Appropriate.
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A  Appropriate; CM  cardiomyopathy; ECG  electrocardiogram; EPS  electrophysiological study; GDMT  guideline-directed medical therapy; LV  left ventricular;
LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; NICM  nonischemic cardiomyopathy; NSVT  nonsustained ventricular tachy-
cardia; R  Rarely Appropriate; RV  right ventricular; SCD  sudden cardiac death; VF  ventricular fibrillation; VT  ventricular tachycardia.Figure 14. Primary Prevention: Comorbidities (Rarely Appropriate Indications)CRT  cardiac resynchronization therapy; HF  heart failure; IV  intravenous; VAD  ventricular assist device.
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Appropriate Use Criteria for ICD/CRT March 26, 2013:1318–68Figure 15. CRT: No Prior Implant—Ischemic CardiomyopathyA  Appropriate; amb  ambulatory; CRT  cardiac resynchronization therapy; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appro-
priate; NYHA  New York Heart Association; R  Rarely Appropriate.Figure 16. CRT: No Prior Implant—Nonischemic Cardiomyopathy
A  Appropriate; amb  ambulatory; CRT  cardiac resynchronization therapy; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appro-
priate; NYHA  New York Heart Association; R  Rarely Appropriate.
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March 26, 2013:1318–68 Appropriate Use Criteria for ICD/CRTFigure 17. CRT: No Prior Implant—LVEF >35% of Any Etiology (ICD Indicated)amb  ambulatory; CRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator; LBBB  left bundle branch block; LVEF  left ventricular ejection
fraction; M  May Be Appropriate; NYHA  New York Heart Association; R  Rarely Appropriate.Figure 18. CRT: No Prior Implant—LVEF <35% of Any Etiology (NYHA Class IV on IV Inotropic Support)CRT  cardiac resynchronization therapy; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association.
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Appropriate Use Criteria for ICD/CRT March 26, 2013:1318–68Figure 19. CRT: No Prior Implant—Pre-Existing or Anticipating RV Pacing With a Clinical Indication for ICD or Pacemaker
Implantation
A  Appropriate; amb  ambulatory; CRT  cardiac resynchronization therapy; LVEF  left ventricular ejection fraction; M  May Be Appropriate; NYHA  New York Heart
Association; R  Rarely Appropriate; RV  right ventricular.Figure 20. Refractory Class III/IV Heart Failure <3 Months Post Revascularization and/or <40 Days Post-MIA  Appropriate; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; M  May Be Appropriate; MI  myocardial infarction; R  Rarely Appropriate.
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This document summarizes the assessed levels of appropri-
ateness for a variety of clinical scenarios involving the
implantation of ICD or CRT devices, including: 1) initial
implantation of ICDs (for primary or secondary prevention
indications) or CRT devices; 2) generator replacements
with pre-existing CIEDs; and 3) choice of dual-chamber, as
opposed to single-chamber, ICDs in specific clinical situa-
tions. These appropriate use criteria are meant to act as a
guide in clinical decision making regarding appropriate
patient selection and the timing of device implantation for
ICDs or CRT devices. However, the writing group feels it
is important to acknowledge that patients may not always fit
neatly within a given clinical scenario and that clinical
judgment is necessary for assessing individual patients.
The appropriate use criteria should be used in conjunc-
tion with the ACC/AHA/HRS 2008 Guidelines for
Device-Based Therapy of Cardiac Rhythm Abnormalities
and the 2012 focused update (9,29), and are meant to
provide additional guidance concerning the decision to
implant ICDs and CRT devices in a variety of clinical
scenarios that may or may not be represented in the
guidelines, often providing additional guidance in areas
where there are gaps in the guidelines. This AUC document
also highlights scenarios where these conditions and recom-
mendations may be modified by patient comorbidities or
limitation of life expectancy because of coexisting diseases.
9.1. ICDs: Initial Implantation
Clinical scenarios involving the implantation of ICDs were
separated into primary and secondary prevention indica-
tions, as these represent unique patient populations. Mod-
ifying considerations, such as LVEF or NYHA class, were
included for specific clinical scenarios when deemed appro-
priate by the writing group based on the evidence and
enrollment criteria in previous clinical trials combined with
clinical judgment based on practice experience with real-
world populations.
A. Secondary Prevention ICD Implantation
Secondary prevention ICD indications included patients
presenting with sustained VT, VF, or syncope with high-
risk characteristics. Clinical scenarios included a variety of
accompanying acute and chronic conditions that could
modify consideration of the risk of subsequent recurrence of
sustained ventricular arrhythmias or sudden cardiac death.
Scenarios modified by LVEF, presence or absence of
CAD or other structural heart disease, revascularization
procedure, timing of sustained VT/VF from MI or revas-
cularization procedure, and single or recurrent nature of
arrhythmias are described in Tables 1.1 to 1.7. Syncope
without clinically documented sustained ventricular ar-
rhythmias modified by presence or absence of CAD or
structural heart disease, LVEF, or EP testing results are cdescribed in Tables 1.8.1 to 1.8.3, whereas hemodynami-
cally stable VT associated with structural heart disease
modified by type of underlying heart disease, LVEF, and
outcome of ablation are described in Table 1.9.
VF or Sustained Polymorphic VT
Scenarios in which patients presented with VF or sus-
tained polymorphic VT in the setting of coronary artery
disease, modified by timing post-MI and timing post-
revascularization, or occurring in the setting of exercise
testing are described in Tables 1.1 to 1.4 (Figs 1 and 2).
onomorphic VT was excluded from these early post-
nfarct scenarios as it was felt that a more uniform tachy-
ardia typically represents a stable substrate that is often
elated to re-entry, and therefore, the risk of arrhythmia
ecurrence may be higher than that seen for patients with
olymorphic VT/VF. Sustained monomorphic VT occur-
ing within the first 48 to 72 h of myocardial infarction is
ssociated with more extensive myocardial damage, is an
ndependent predictor of in-hospital mortality, and is asso-
iated with a poor 1-year outcome (33,34).
ICD implantation was considered Rarely Appropriate for
ost of these scenarios where VF or polymorphic VT
ccurred in the setting of acute (48 h) MI, particularly in
he setting of preserved or only mild to moderately reduced
V systolic function, except for the case where nonsustained
T occurred 4 days post-MI and sustained VT/VF was
hen induced at EP testing (Table 1.1, Fig. 1). This is
onsistent with clinical evidence where ICD implantation
hould not be recommended for arrhythmias considered
completely reversible.” However, indications were rated
ay Be Appropriate if LVEF was35%. These indications
over patients with LV dysfunction that could have been
re-existing, as these scenarios did not include any prior
ssessment of LVEF, or little chance for recovery of LV
unction (in the absence of revascularization in some sce-
arios). ICD implantation was rated as Appropriate for
bstructive CAD with coronary anatomy not amenable to
evascularization if LVEF 35%. The presence of obstruc-
ive coronary disease that is not amenable to revasculariza-
ion could place the patient at continued risk for recurrent
rrhythmias and, therefore, may not qualify as a “completely
eversible” cause.
Sustained VT/VF occurring in the setting of nonischemic
eart disease, including genetic diseases, infiltrative cardio-
yopathy, or myocarditis, as well as no detectable structural heart
isease are described in Tables 1.5 to 1.7 (Figs. 3 and 4). Many of
hese scenarios are not specifically addressed in the guide-
ines or clinical trials, and represent a relatively small
ercentage of the population undergoing ICD implantation.
herefore, clinical judgment based on review of limited
vidence is required when making these decisions.
yncope
Scenarios involving syncope included those with and
ithout underlying structural heart disease or concomitant
oronary artery disease. In patients without structural heart
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occurring in the setting of long QT syndrome regardless of
treatment with beta-blockers, a Brugada ECG pattern
regardless of findings at invasive electrophysiological test-
ing, and catecholaminergic polymorphic VT (Table 1.8.1,
Fig. 5). In contrast, ICD implantation was rated as Rarely
Appropriate in patients with unexplained syncope who have
a normal heart and normal ECG and do not have a genetic
condition associated with sudden death, or when syncope
occurs in patients with normal LV function and idiopathic
VT (e.g., RV outflow tract VT or idiopathic LV VT)
whether or not ablation had been attempted. The latter is
consistent with the good prognosis of patients with idio-
pathic VT.
In the setting of coronary artery disease, scenarios were
modified by LVEF (Table 1.8.2, Fig. 6). In patients with
unexplained syncope, prior MI, and an LVEF 35%, ICD
implantation was considered Appropriate regardless of the
findings of EP study. In the setting of a mildly reduced
LVEF (36% to 49%) and prior MI, ICD implantation was
considered Appropriate only if EP study revealed inducible
sustained VT or VF, but was rated as May Be Appropriate
if the EP study failed to define a cause, regardless of
revascularization status.
In patients with nonischemic structural heart disease and
syncope, scenarios were modified by type of heart disease
and LVEF (Table 1.8.3, Fig. 7).
Sustained Hemodynamically Tolerated Monomorphic VT
Hemodynamically tolerated sustained monomorphic VT
was considered separately from hemodynamically unstable
VT or VF, given the potential differences in arrhythmia
substrate as well as the response of VT to catheter ablation.
When occurring in the setting of LVEF 35%, regardless
of the underlying disease process or history of VT ablation,
ICD implantation was considered Appropriate (Table 1.9,
Fig. 8) (35). With a normal LVEF (50%) and hemody-
amically tolerated monomorphic VT, ICD implantation
as rated Appropriate in the setting of prior MI or
onischemic dilated cardiomyopathy in the absence of VT
blation, but it was rated as May Be Appropriate if
uccessful VT ablation was performed.
. Primary Prevention ICD Implantation
n the absence of sustained VT/VF or syncope, primary
revention ICD implantation may be considered in a variety
f scenarios to reduce mortality related to potentially life-
hreatening sustained ventricular arrhythmias. Specific time
eriods for implantation of primary prevention ICDs (i.e.,
0 days after an acute MI, 3 months after revascularization,
nd 3 months after initial diagnosis of a cardiomyopathy)
re described. These time periods were selected for this
ppropriate use document based on prior clinical trials,
uideline documents, or contemporary practice. A “waiting
eriod” following MI is supported by the IRIS (Immediate dRisk-Stratification Improves Survival) trial and DINAMIT
(Defibrillator IN Acute Myocardial Infarction Trial), which
demonstrated no overall survival benefit of ICD therapy
when devices were implanted very early (within 30 or 40
days) following MI (30,31). Scenarios in this section are also
modified by type of heart disease, LVEF, NYHA functional
class, and/or duration of medical therapy (Tables 2.1 to 2.5,
igs. 9 to 13).
iming Post-MI or Revascularization and
lectrophysiological Testing
Initial primary prevention ICD trials utilized EP testing
n risk stratification. Many of the scenarios in Tables 2.1.1
nd 2.1.2 take into account some of the shorter time periods
ost-MI where limited trial data are available. The defini-
ion for MI has evolved in recent years (23,25). For
ontemporary practice, the diagnosis of MI should be made
ccording to the most recent statement and future trials
hould precisely define MI and other diagnoses critical to
ajor entry criteria. The MUSTT study enrolled patients
ith CAD, LVEF 40%, and asymptomatic, nonsustained
T (36). The qualifying arrhythmia had to have occurred 6
onths or less before enrollment, and 4 or more days after
he most recent MI or revascularization procedure. The
tudy showed that EP-guided therapy with ICDs, but not
ith antiarrhythmic drugs, reduced the risk of sudden death
n these patients. However, 80% of randomized patients
ad suffered their most recent MI more than 1 month
efore enrollment. Thus, because few patients were enrolled
n the first month post-infarction, the utility of EP study in
hat time period is uncertain.
These scenarios are also modified by the presence or
bsence of revascularization. To qualify for enrollment,
ADIT II required a waiting period of at least 3 months
ollowing coronary revascularization. In contrast, patients
ere eligible for enrollment in MUSTT 4 days following
evascularization, and 56% of patients enrolled in this trial
nderwent prior CABG at some point in time (36). How-
ver, post-hoc analysis of MUSTT revealed that the occur-
ence of postoperative NSVT, especially within 10 days after
ABG, portends a far better outcome than when it occurs
n non-postoperative settings (37). As there are limited data
elated to EP testing very early following revascularization
rocedures, and available data suggest that NSVT in this
arly period may represent a less specific risk factor for
uture events, decisions related to timing of EP testing
hould be individualized. As in other areas of this AUC
ocument, panel members were asked to evaluate scenarios
here gaps in the guidelines exist, and further investigation
ay be warranted.
re-Existing Cardiomyopathy or
ermanent Pacemaker Needed
When a pre-existing cardiomyopathy with LVEF 35%
ad been present for at least 3 months, regardless of the
ause, ICD implantation was rated Appropriate even 40
ays after the acute MI (Table 2.1.3). The rationale is that
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utable to acute MI and would not be likely to recover.
Furthermore, when the LVEF is severely reduced (35%)
and the patient requires permanent pacemaker implantation
early (40 days) following MI, ICD therapy was rated
Appropriate (Table 2.1.4). Although these scenarios are not
specifically addressed in clinical trials, this is a logical
decision from the standpoint of cost and patient safety. If
little or no improvement in LV function is expected, the
need for a second procedure in 3 months would expose
the patient to unnecessary risk. When a patient requires
pacing early (40 days) post-MI, implantation is also
justified to avoid the expense and risk of implanting a
pacemaker followed by replacement with an ICD after
the 40-day interval. In the REPLACE registry (RE-
PLACE: Implantable Cardiac Pulse Generator Replace-
ment Registry), a high complication rate of 15.3% was
observed in patients undergoing planned transvenous lead
addition for replacement or upgrade to a device capable of
additional therapies (38).
When recent percutaneous coronary intervention or cor-
onary artery bypass grafting had been performed, the tech-
nical panel determined that an ICD implantation was
Appropriate when there was a known pre-existing cardio-
myopathy present for 3 months or when there was an
indication for pacing and the LVEF was 35% (Table 2.2,
Fig. 10).
Duration of Guideline-Directed Medical Therapy
Once a patient with a nonischemic cardiomyopathy is on
guideline-directed therapy for at least 3 months, ICD
implantation was rated Appropriate for LVEF 35% and
NYHA class I to III symptoms (Table 2.4). It is generally
recommended that patients receive a period of guideline-
directed medical therapy following a new diagnosis of
nonischemic cardiomyopathy with the hope that LV func-
tion will improve. ICD implantation within 3 months of a
newly diagnosed cardiomyopathy (LVEF 35%) was con-
sidered Rarely Appropriate in most instances (Table 2.4,
Fig. 11). Similarly, in the setting of an ischemic cardiomy-
opathy without recent MI, ICD implantation was deemed
Appropriate only after the patient had received guideline-
directed medical therapy for at least 3 months, unless
nonsustained VT had been present and EP study revealed
inducible sustained VT/VF (Table 2.3). In patients with
ischemic cardiomyopathy status post-MI (40 days) with
an LVEF 30% and without revascularization within 3
months (MADIT II [Multicenter Automatic Defibrillator
Implantation Trial II] criteria), ICD implantation was rated
Appropriate regardless of duration of heart failure therapy
(Table 2.2).
The other potential exception to the 3-month waiting
period is when pacing is needed after recent valve surgery
with an incidental bypass graft, and severe LV function
(LVEF 35%) is not likely to improve (Table 2.4). tC. Comorbidities
Based on existing data, the risks and benefits of ICD
therapy may be modified by specific coexisting comorbidi-
ties, even when other primary prevention indications exist
for ICD implantation (39–43). Much of these data are
based on post hoc analyses from clinical trials, registries, or
small studies. Comorbidities may limit life expectancy or
enhance risk. The potential risks and benefits should be
assessed on an individual basis, and options should be
discussed between the healthcare provider and the particular
patient. The writing group created scenarios with specific
comorbidities that may modify decision making regarding
primary prevention ICD implantation when the ICD would
otherwise be deemed Appropriate.
The only comorbidities that were felt to make ICD
implantation Rarely Appropriate were a life expectancy 1
ear, age 90 years with NYHA class I symptoms, inability
o understand or provide informed consent in the absence of
healthcare proxy, ongoing drug abuse, documented non-
ompliance with medical therapy and follow-up, unresolved
nfection associated with the risk of hematogenous seeding,
dvanced psychiatric impairment, or certain NYHA class IV
atients (Table 3.1, Fig. 14). There are many degrees and
easons for non-adherence to medical therapy and follow-
p, some of which can be improved through better educa-
ion and enhanced access to care. Therefore, the individual
atient situation and timing of the procedure should clearly
e considered prior to determining eligibility for ICD
herapy. Amongst the considered comorbidities, ICD im-
lantation was deemed to be Appropriate in the setting of
evere symptomatic peripheral vascular disease and NYHA
lass II to III symptoms and NYHA class IV patients on
aiting list for heart transplant. ICD implantation was
ated as May Be Appropriate in the setting of other
ntermediate comorbidities such as a life expectancy of 1 to
years, age80 years with NYHA class II to III symptoms,
r severe cognitive impairment (with health proxy who
onsents to an ICD).
Although sudden cardiac death increases with age, elderly
atients have been underrepresented in clinical trials, and
omorbidities in the elderly might attenuate the benefit of
CD therapy. There is evidence that older patients with
CDs have worse survival than younger patients because
eath related to comorbidities in elderly patients outweighs
he proportion of deaths related to ventricular arrhythmias
44). In addition, characteristics of patients receiving ICDs
n clinical practice may differ from those enrolled in ran-
omized clinical trials. For example, in primary prevention
CD trials, the median age was only 60 to 67 years
11,36,45). In the ACT (Advancements in ICD Therapy)
egistry, which included 4,566 patients who underwent their
rst ICD or CRT plus defibrillator implantation, 12% were
80 years old (75% of whom received devices for primary
revention), which was similar to the NCDR registry at that
ime where 12.4% of patients receiving ICDs were 80
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imately 17% of patients in the NCDR registry are now 80
years old, and 0.9% are 90 years old, suggesting an aging
population receiving ICDs (47).
The role of ICD therapy for primary prevention of
sudden death in patients with chronic kidney disease (with
or without dialysis) was rated as May Be Appropriate.
Multiple studies have questioned the benefit of ICD im-
plantation in patients with chronic kidney disease, especially
when on dialysis (48,49). Chronic kidney disease and
associated comorbidities reduce long-term survival of pa-
tients and limit the beneficial impact of ICD therapy. In
addition, patients with chronic kidney disease who are on
dialysis appear to be at higher risk of complications related
to ICD implantation, including increased risks related to
bleeding and infection (41).
In the setting of Class IV heart failure, if the patient was
not deemed a candidate for transplantation, CRT, or
ventricular assist device, ICD therapy was rated Rarely
Appropriate when outpatient continuous intravenous ino-
tropic therapy was planned (Table 3.1). This is consistent
with a low survival rate at least 1 year for NYHA class IV
patients with drug-refractory heart failure who are not
candidates for cardiac transplantation or CRT.
The survival benefit or complications related to primary
prevention ICD implantation appears to be modified by
age, LVEF, or pre-existing conditions such as chronic renal
disease and peripheral arterial disease (39–43). A simple
risk score incorporating peripheral arterial disease, age 70
years, creatinine 2.0 mg/dl, and ejection fraction 20%
accurately predicted 1-year mortality in one recent study
(42). Therefore, possible adverse effects of comorbidities
should be openly discussed with potential ICD recipients
before implantation to enhance the informed decision-
making process.
The subcutaneous ICD system is not addressed in this
document as further study is necessary to determine whether
benefits might outweigh risks in patients who currently
appear to derive little benefit from ICD therapy due to
comorbidities and competing mortality risks.
9.2. CRT Devices
Stratification of ejection fraction (separating LVEF 30%
from LVEF 31% to 35%), NYHA class (class I through
ambulatory class IV), and QRS morphologies (considering
LBBB QRS morphologies separate from non-LBBB QRS
morphologies) were selected based on data from recent
clinical trials.
Recent meta-analyses of CRT trials have suggested that
the benefit of CRT is dependent on QRS duration, with a
significant benefit associated with CRT in patients with
QRS 150 ms, but not in patients with QRS 150 ms
(20,21). Clinical response to CRT is also dependent on
QRS morphology, with the greatest response for patients
with LBBB and QRS 150 ms (50). There is also evidencethat patients with RBBB morphology may not demonstrate
benefit from CRT (51).
Recent data demonstrate the benefit of CRT combined
with ICD therapy in patients with less severe heart failure
(NYHA class I to II), LVEF 30%, and QRS duration of
130 ms (52). In MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial–Cardiac Resynchroniza-
tion Therapy), the superiority of CRT was driven by a 41%
reduction in the risk of heart-failure events, that was evident
primarily in a pre-specified subgroup of patients with a QRS
duration of 150 ms. MADIT-CRT was limited to pa-
tients with ischemic cardiomyopathy (NYHA class I or II)
and nonischemic cardiomyopathy (NYHA class II only), so
no conclusions can be made for nonischemic patients with
class I heart failure based on the results of this study.
Scenarios modified by QRS duration, QRS morphology,
NYHA class, type of heart disease, LVEF, need for inotro-
pic support, other clinical indications for CIED therapy
with anticipated frequent need for RV pacing, and timing
post-MI or revascularization are described in Tables 6.1 to 6.5
Figs. 15 to 20).
In the setting of an LVEF35% with a narrow QRS and
plan to implant an ICD or pacemaker in a patient with
anticipated need for frequent RV pacing (40% of the
time), CRT implantation was rated Appropriate regardless
of NYHA class, even if the intrinsic QRS was narrow
(Table 6.4). However, if anticipated pacing was 40% of
the time, CRT appropriateness was rated as May Be
Appropriate. This is consistent with prior studies implicat-
ing the deleterious consequences of RV pacing, specifically
suggesting that 41% to 50% RV pacing may result in a
higher risk of heart failure, particularly in the setting of
pre-existing LV dysfunction (16,53–55).
9.3. Generator Replacement
There are limited data about the management of patients
presenting for elective generator replacements in the setting
of previously implanted ICD or CRT devices that are
nearing end-of-life. Over a patient’s life span, clinical
situations evolve and previously present conditions that
merited ICD or CRT implantation may change. The
individual patient’s clinical status and concomitant illnesses
may evolve so that considerations may include not only
replacement of the pulse generator, but also potentially
changing the type of device (e.g., from an ICD to a
pacemaker). Furthermore, the clinical evidence for CIED
placement may evolve over time, with ongoing research and
availability of new trial data. Once patients have received
appropriate ICD therapy for ventricular arrhythmias, they
are subsequently considered “secondary prevention” at the
time of generator replacement in the NCDR. There is
currently a paucity of data related to generator replacement
in patients who received primary prevention ICDs but have
not experienced clinically relevant arrhythmias since initial
implantation, and generator replacement is often still per-
formed regardless of LVEF at follow-up. However, the
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“upgrade” of a device is not without risk. Therefore, the
indications seek to assess appropriateness for a variety of
clinical scenarios related to either “replace the pre-existing
CIED” or “downgrade” ICDs or CRT-ICDs to pacemak-
ers. A recent editorial discussed the potential risks and
financial implications related to ICD generator replace-
ments and the need for additional clinical trials to better
understand which patients should undergo generator re-
placements (56).
Scenarios that consider original indication for the device,
life expectancy, or LVEF recovery are described in Tables
.1 to 4.4. Replacement of a CRT-ICD with a CRT-
acemaker when the LVEF had improved since initial
evice implantation for primary prevention indications was
ated as May Be Appropriate (Table 4.3). These ratings of
ay Be Appropriate are consistent with the gaps of knowl-
dge in this area, as there is a lack of data examining sudden
eath or ventricular arrhythmia risk following some recovery
f LV function.
9.4. Dual-Chamber Versus Single-Chamber ICDs
Clinical trials evaluating the mortality benefit of ICD
therapy for primary or secondary prevention have mostly
involved implantation of single-chamber devices. While
dual-chamber devices are associated with higher complica-
tion rates related to implantation (57,58), proponents of
dual-chamber devices suggest potential clinical benefits of
the atrial lead. Theoretical benefits could include ventricular
versus supraventricular arrhythmia discrimination and un-
necessary shock reduction, although this remains a subject
of debate and is discussed in the following text. A recent
report from the NCDR ICD registry demonstrates marked
variation in single- versus dual-chamber ICD usage in the
United States (59).
The potential benefit of single- versus dual-chamber
pacemaker implantation has been recently addressed in a
consensus document, but additional considerations may
apply to ICD therapy (17). The decision to implant a
dual-chamber ICD, rather than a single-chamber ICD, may
employ a variety of clinical considerations including the
potential need for pacing due to underlying conduction
system disease, potential impact of drugs on sinus or
atrioventricular conduction, potential suppression of ven-
tricular arrhythmias with atrial pacing in specific disorders,
or relative value of device algorithms in arrhythmia discrim-
ination. For scenarios where the QRS was wide, the panel
was instructed to assume that the patient does not otherwise
meet criteria for CRT implantation.
Scenarios evaluating the need for dual-chamber ICDs are
described in Tables 5.1 to 5.4. These scenarios are modified
based on concomitant conduction system disease or pacing
indications, coexisting atrial arrhythmias with plans for
rhythm versus rate control, known slow ventricular arrhyth-
mias, or other disorders (congenital long QT or hypertro-
phic cardiomyopathy).Dual-chamber ICD implantation was considered Appro-
priate for congenital long QT syndrome (Table 5.4). How-
ever, the latter rating of Appropriate should not be consid-
ered “required,” as single-chamber devices may be preferable
in some situations of long QT syndrome.
Implantation of a dual-chamber device was also consid-
ered Appropriate by the panel in certain scenarios that
would not meet standard guidelines for pacemaker implan-
tation (i.e., in the setting of asymptomatic sinus bradycardia,
history of paroxysmal atrial arrhythmias, or slow ventricular
arrhythmias where “slow VT” overlaps with the sinus
tachycardia rate) (Tables 5.1 and 5.3). Although not a
linical indication for dual-chamber pacing per se, the
ppropriate rating of dual-chamber device selection for
atients with paroxysmal atrial arrhythmias may reflect
erceived benefits related to arrhythmia discrimination or
etection of “silent” atrial arrhythmias with insertion of an
trial lead.
The only clinical situation in which implantation of a
ual-chamber device was rated as Rarely Appropriate was in
he setting of long-standing persistent or permanent atrial
brillation or flutter in patients in whom cardioversion or
hythm control strategies are not planned. All other clinical
cenarios, including hypertrophic cardiomyopathy with a
ide or narrow baseline QRS and conduction system
isease that would not meet guideline criteria for pacemaker
mplantation and not previously mentioned, were rated as
ay Be Appropriate. Even a narrow QRS complex with a
ormal PR interval was rated as May Be Appropriate by the
echnical panel (Table 5.2), further highlighting differences
etween the thresholds for inserting an atrial lead in a
atient undergoing pacemaker implantation compared with
CD implantation.
9.5. Application of Pre-Specified Cutoffs
The requirements for specific waiting periods after revascu-
larization, diagnosis of a new cardiomyopathy, or recent MI,
as well as stratification of QRS duration, LVEF, and other
criteria such as percentage of RV pacing were made based
on enrollment criteria for clinical trials. However, these
criteria varied between various clinical trials. For example,
the criterion of 40 days after MI is well established by
prospective randomized clinical trials including DINAMIT
(6 to 40 days) and IRIS (5 to 31 days) (30,31). In contrast,
the waiting period of 3 months after diagnosis of a new
cardiomyopathy or revascularization procedure is arbitrary.
Although guideline documents identify specific criteria
for QRS duration or LVEF, they do not require a
mandatory time lapse following heart failure diagnosis or
revascularization. The absence of evidence regarding a
benefit of ICD implantation during unstudied time
frames is not the same as evidence of “no benefit.” This is
probably why many of these scenarios were rated as May
Be Appropriate.
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Understanding of AUC Ratings
In creating and rating clinical scenarios, the goal was to
focus on the most common clinical situations encountered
in practice where an ICD or CRT may be considered. The
goal of rating appropriateness is to help inform clinical
decision making in areas, particularly in areas where there
may be “gaps” in the guidelines, rather than to establish
rules by which decisions should be made in clinical practice.
Although the appropriate use ratings reflect a general
assessment of when ICD or CRT devices may or may not be
useful for specific patient populations, physicians and other
stakeholders should continue to acknowledge the pivotal
role of clinical judgment in determining whether CIED
implantation is indicated for an individual patient.
Clinical indications rated as May Be Appropriate also
require individual physician judgment and understanding of
the individual patient to best determine the usefulness of
CIED implantation for a particular clinical scenario. The
rating of May Be Appropriate (4 to 6) should not exclude
the use of ICD or CRT devices for such patients. It is
important to recognize when reviewing the aforementioned
criteria that ratings in this middle category may represent
either the lack of sufficient data to inform the decision or the
fact that, depending on other clinical factors not considered
in the brief scenario, device implantation may or may not be
considered beneficial. The wide breadth of scenarios rated as
May Be Appropriate raises the importance of recognizing
the role of applying clinical judgment to decision making
when encountering patients who broadly meet these criteria,
as well as for the importance of advocating for future clinical
trials to better inform decision making in these scenarios.
In addition, physicians recognize that an attribution of
Appropriate to a clinical scenario does not necessarily
indicate that implantation is mandatory but only that it is
reasonable given existing data. There may be some clinical
scenarios in which the use of ICD or CRT devices for an
indication considered Appropriate does not always represent
reasonable practice. Accordingly, the AUC for ICD/CRT
devices are intended to evaluate overall patterns of care for
device implantation rather than adjudicating specific cases.
For situations where there is substantial variation between
the appropriate use rating and what the clinician believes is
best for the particular patient, further options such as a
second opinion may be considered. It is anticipated that
physicians practicing good evidence-based care will implant
a mix of cases meeting both Appropriate and May Be
Appropriate categories. However, if there are marked vari-
ations in patterns when compared with national bench-
marks, further examination of the patterns of care might be
helpful in identifying explanations for these variations.
Thus, appropriate use criteria may be applied in many
ways, for example, decision support algorithms and educa-
tional tools may be developed. Appropriate use criteria
should be considered in concert with the guidelines. Theindications in AUC documents are more granular and cover
more specific patient scenarios that are not specifically
addressed in guidelines. Where there is overlap with the
device-based therapy guidelines, the ratings are consistent
with the guideline recommendations. Generally, criteria
that have been deemed Appropriate or May Be Appropriate
in these scenarios often meet Class I, IIa, or IIb criteria in
guideline documents, are supported by a critical mass of
existing data, or were deemed by the technical panel to meet
sufficient clinical judgment to be reasonable and appropri-
ate. For further details, see the Guideline Mapping and
References.
The manner in which other pertinent information may
modify clinical decisions is made most clear by the comor-
bidities section. This section demonstrates how coexistence
of other medical issues may modify the decision to implant
an otherwise indicated or appropriate ICD. Thus, it is clear
that clinical decision making is complex, and the described
scenarios should be used as a guide to work in accompani-
ment with other clinical information.
Finally, there are differences related to ICD or CRT
implantation and previous AUC documents related to other
subjects such as imaging or catheterization. The decision to
implant a device results in long-term, specialized follow-up
and carries anticipated hospitalization costs that accumulate
over time. There is a wide array of patient characteristics
that could potentially affect clinical decision making that
cannot be described in a limited number of brief case
scenarios. This raises the importance of understanding these
criteria as a “guide,” rather than as a list of “do” or “do not
do” specifications. The included scenarios do not encompass
all possible clinical situations that may be encountered in
practice. Therefore, specific clinical situations not addressed
in these scenarios should be considered in their unique
contexts.
9.7. Reimbursement and Disclaimer
It is the intent of this document to address good medical
practice, independent of reimbursement. Some of the sce-
narios that are deemed Appropriate by the appropriate use
criteria may not currently qualify for insurance coverage. For
patients, physicians, and insurers, these distinctions are of
critical importance because commitment to patient-
centered care may warrant implantation of a device appro-
priate for the individual patient’s situation, but it may not fit
precisely into a covered indication as defined by coverage
policy and requires use of best clinical judgment. Additional
evidence-based documents addressing clinical scenarios not
specifically covered in currently available guideline docu-
ments may help address reimbursement decisions in the
future.
9.8. Application of Criteria
Facilities and payers may use these criteria to review
procedural indications. Payers may use the criteria in their
deliberations about coverage decisions. Furthermore, ser-
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considered in the context of the clinical situation. Namely,
supporting documentation that informed the clinical deci-
sion should be sought, as other factors beyond those
described in the brief clinical scenarios included in this
document may have entered into clinical decision making.
Given recent concerns regarding the potential frequency
of “overuse” or inappropriate device implantation, concerns
related to reimbursement for device implantation, and
Department of Justice investigations, it is important to
weigh how these appropriateness criteria fit with existing
guidelines and statements regarding national coverage de-
terminations. Many of the clinical scenarios were rated as
May Be Appropriate (33%), which demonstrates the need
for collaborative approaches to establishing coverage deci-
sions in order to address the “disconnect” between reim-
bursement criteria and guidelines, promoting evidence-
based care.
Although not specifically addressed in this document or
in the Department of Justice investigation, “underuse” of
ICD therapy has been demonstrated (60,61). These appro-
priateness criteria may be used to create algorithms or tools
that help guide decision making or help understand resource
utilization. This may be useful at the point of care where
decisions are being made in the hospital or office setting. If
these data are used to evaluate performance of physicians or
facilities, they should only be used with other measures of
quality. For example, establishing prospective pre-
authorization for procedures may work best once a retro-
spective review has identified a pattern of inappropriate use.
The AUC criteria outlined in this document are based on
the most current data. Retrospective application of the
ratings to coverage decisions on previously performed pro-
cedures may not be valid, as those decisions could not have
been made on evidence that was not available at the time the
decision was made.
The primary objective of this report was to describe
real-life factors that play a role in decisions for ICD and
CRT implantation, while providing guidance regarding
device implantation for scenarios that are not specifically
addressed in the guidelines. The relationship of these
criteria to existing guidelines was provided to the technical
panel. In addition, extensive links to clinical trials and other
literature regarding the role of ICD and CRT in each
clinical scenario were provided to technical panel members.
Further research is needed to analyze patient outcomes for
scenarios where there was disagreement among panel mem-
bers, that is, rated as both Appropriate and Rarely Appro-
priate by different panel members. When new clinical trials
and other data are published, it will be necessary to
incorporate this new information in future iterations of the
AUC for ICD and CRT implantation.
In conclusion, this document represents the current
understanding of the clinical utility of ICD and CRT
implantation in clinical practice as measured by physicians
with a variety of backgrounds and areas of expertise. It is thegoal that these criteria will help provide a guide to inform
medical decisions and help clinicians and stakeholders
understand areas of consensus as well as uncertainty, while
identifying areas where there are gaps in knowledge that
warrant additional investigation.
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Literature Review
The technical panel members were asked to refer to the
relevant guidelines for a summary of the relevant literature,
guideline recommendation tables, and reference lists pro-
vided for each indication table when completing their
ratings (see Guideline Mapping and References Online
ppendix).
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